[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 83 of about 83
1. González-Lagunas J, Alasà-Caparrós C, Vendrell-Escofet G, Huguet-Redecilla P, Raspall-Martin G: Polymorphous low-grade adenocarcinoma of the nasal fossa. Med Oral Patol Oral Cir Bucal; 2005 Aug-Oct;10(4):367-70
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low-grade adenocarcinoma of the nasal fossa.
  • An unusual case of a T4N2CMx polymorphous low grade adenocarcinoma located in the nasal fossae and extending to the pterygoid area is presented.
  • [MeSH-major] Adenocarcinoma / pathology. Nose Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Aged. Female. Humans. Nasal Cavity / pathology. Neck Dissection. Osteotomy, Le Fort. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16056192.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Carvalho A, Amaral Mendes R, Carvalho D, Carvalho JF: [Osteonecrosis of the mandible induced by intravenous bisphosphonates in oncological patients]. Acta Med Port; 2008 Sep-Oct;21(5):505-10
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1: Seventy one years-old male patient, undergoing standard antineoplastic therapy and bisphosphonates due to multiple myeloma 4 years ago was referred to an oral surgeon because of bone exposure, after dental extraction.
  • Case 2: Seventy years-old female patient undergoing treatment with bisphosphonates for adenocarcinoma of the breast was referred to an appointment of oral surgery due to bony exposure.
  • The increasing incidence of this new entity, its physiopathological mechanisms and the nonexistence of consensual and evidence-based treatments, calls for a special attention on prevention, with special emphasis on a careful clinical examination of the oral cavity previously to the establishment of a therapeutic approach with intravenous bisphosphonates in oncological patients.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Breast Neoplasms / drug therapy. Female. Humans. Male. Multiple Myeloma / drug therapy

  • Genetic Alliance. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187694.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  • [Chemical-registry-number] 0 / Diphosphonates
  •  go-up   go-down


3. Todoroki T, Murata S, Nakagawa Y, Ohkohchi N, Morishita Y: A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report. Int Semin Surg Oncol; 2006;3:22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report.
  • BACKGROUND: Tumor spread beyond the peritoneal cavity in cases of papillary serous adenocarcinoma of the unknown primary (CUP) is a rare late event and carries a poor prognosis.
  • Pathological examination revealed the tumors to be metastases of a papillary serous adenocarcinoma with a psammoma body of CUP.
  • All surgical resections followed the modified FAM (5FU, Adriamycin; ADM, MMC) regimen, including protracted dairy oral administration of UFT or 5'-FDUR, Cimetidine and PSK (protein-bound polysaccharide K) as an immunomodulator or biological response modifier in conjunction with intermittent one-day continuous infusion (ADM+MMC) or intermittent single bolus injection of ADM+MMC.
  • CONCLUSION: Aggressive resection surgery followed by effective adjuvant chemotherapy is necessary for surviving long time without relapse of poorly prognostic patients with metastases outside of the abdominal cavity from peritoneal papillary serous adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Oncology (Williston Park). 2001 Mar;15(3 Suppl 5):16-20 [11301835.001]
  • [Cites] Jpn J Cancer Res. 2001 Jun;92(6):704-9 [11429061.001]
  • [Cites] Bull Cancer. 2002 Oct;89(10):869-75 [12441278.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S59-66 [12915904.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1003-10 [14997197.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):443-9 [15816609.001]
  • [Cites] DICP. 1990 Mar;24(3):289-95 [2138376.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1091-4 [2400962.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):15-21 [9210704.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • (PMID = 16930493.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1574334
  •  go-up   go-down


Advertisement
4. Andreadis D, Nomikos A, Epivatianos A, Poulopoulos A, Barbatis C: Basaloid squamous cell carcinoma versus basal cell adenocarcinoma of the oral cavity. Pathology; 2005 Dec;37(6):560-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma versus basal cell adenocarcinoma of the oral cavity.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry


5. Paleri V, Robinson M, Bradley P: Polymorphous low-grade adenocarcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg; 2008 Apr;16(2):163-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low-grade adenocarcinoma of the head and neck.
  • PURPOSE OF REVIEW: Polymorphous low-grade adenocarcinoma is an entity described in 1984.
  • The natural history of polymorphous low-grade adenocarcinoma is distinct from other malignant salivary tumours.
  • RECENT FINDINGS: Polymorphous low-grade adenocarcinoma is a slow-growing tumour that is locally invasive.
  • The most common presentation is that of a lump in the oral cavity, usually on the palate.
  • Diagnosis is established after a biopsy because cytological studies are not helpful.
  • The role of radiation therapy is not clear in the management of polymorphous low-grade adenocarcinoma.
  • SUMMARY: Polymorphous low-grade adenocarcinoma is primarily a pathologic diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327037.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


6. Alvarez-Alvarez C, Iglesias-Rodríguez B, Pazo-Irazu S, Delgado-Sánchez-Gracián C: Colonic adenocarcinoma with metastasis to the gingiva. Med Oral Patol Oral Cir Bucal; 2006 Jan;11(1):E85-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenocarcinoma with metastasis to the gingiva.
  • Metastatic tumors involve the oral cavity, and the most common primary sites are the breast and lung.
  • We report the case of a 62-year-old male who had been diagnosed with sigmoid adenocarcinoma with nodal and liver metastasis, who presented 6 months later with a gingival polypoid tumor, at first considered as a primary neoplasm of gingiva, that was diagnosed in a biopsy as metastatic intestinal adenocarcinoma.
  • The histological evaluation is essential to separate adenocarcinoma from the commoner in this site squamous cell carcinoma, and the immunohistochemical techniques are useful to distinguish metastatic tumor versus primary adenocarcinoma from the minor salivary glands of the area.
  • [MeSH-major] Adenocarcinoma / secondary. Gingival Neoplasms / secondary. Mandibular Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16388302.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Rosbottom KJ, Michie B, Boyce S: Metastasis of recurrent colonic adenocarcinoma to the mouth. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of recurrent colonic adenocarcinoma to the mouth.
  • Colorectal adenocarcinoma is a common cancer; however, reports of metastases to the oral region are uncommon.
  • Oral metastases often indicate disseminated disease, the prognosis is poor and management is often palliative.
  • We report the case of a 73-year-old man with recurrent metastatic disease who presented 2 years following his initial surgery for a left-sided colonic adenocarcinoma with a painful oral tumour.
  • Biopsy confirmed adenocarcinoma with similar features to the original colonic tumour; the patient went on to have palliation of his symptoms with radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Surg. 1975 Jan;33(1):53-6 [1053651.001]
  • [Cites] Br J Oral Maxillofac Surg. 2003 Feb;41(1):3-6 [12576032.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1965 Sep;20:350-62 [14342927.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):355-60 [8746264.001]
  • [Cites] Ann Surg. 1940 Jul;112(1):138-49 [17857618.001]
  • [Cites] Oral Oncol. 2008 Aug;44(8):743-52 [18061527.001]
  • [Cites] J Oral Pathol. 1987 Aug;16(7):362-7 [3117991.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • (PMID = 21754956.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028428
  •  go-up   go-down


8. Damodaran D, Kathiresan N, Satheesan B: Oral cavity metastasis: An unusual presentation of carcinoma prostate. Indian J Urol; 2008 Jan;24(1):112-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral cavity metastasis: An unusual presentation of carcinoma prostate.
  • Oral cavity cancers form the third most common cancers among men in south India.
  • The oral cavity is a very rare site for metastases and has been described in various cancers, particularly lung, breast, kidney and colon carcinoma.
  • Here a very rare case of a buccal metastasis from prostate carcinoma that was originally evaluated as a primary oral cavity malignancy is presented.
  • Histopathological examination of a biopsy of the lesion revealed papillary adenocarcinoma Grade II, nuclear Grade II, which initiated the evaluation of prostate.
  • On evaluation diagnosis of carcinoma prostate was made which was confirmed by immunohistochemistry for PSA.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Sep 20;116(5):740-54 [15849747.001]
  • [Cites] Pathol Int. 1999 Jun;49(6):500-5 [10469392.001]
  • [Cites] J Periodontol. 1999 Apr;70(4):441-4 [10328657.001]
  • [Cites] Br J Oral Maxillofac Surg. 2003 Feb;41(1):3-6 [12576032.001]
  • [Cites] BJU Int. 1999 Dec;84(9):1028-31 [10571628.001]
  • (PMID = 19468372.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2684236
  • [Keywords] NOTNLM ; Oral cavity metastasis / prostate cancer / prostate specific antigen immunohistochemistry
  •  go-up   go-down


9. González-García R, Naval-Gías L, Rodríguez-Campo FJ, Sastre-Pérez J, Gamallo C: Adenocarcinoma of the ethmoidal and nasal mucosa: lateral rhinotomy as a more conservative approach. Acta Otolaryngol; 2006 Aug;126(8):878-80
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the ethmoidal and nasal mucosa: lateral rhinotomy as a more conservative approach.
  • Malignant neoplasms of the nasal cavity and paranasal sinuses are infrequent.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Papillary / diagnosis. Ethmoid Sinus. Nasal Mucosa. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16846933.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


10. Dib LL, Soares AL, Sandoval RL, Nannmark U: Breast metastasis around dental implants: a case report. Clin Implant Dent Relat Res; 2007 Jun;9(2):112-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metastases to the oral cavity and to the jaws are rare; hence, the clinical manifestations of the oral metastasis lesion could frequently be simulating general pathologic entities, making the diagnosis a challenging process to the dental team.
  • PURPOSE: Careful clinical examination is a valuable help in diagnosing oral lesions, which can improve the quality of life of patients and reduce the risks of oral complications.
  • RESULTS: Clinical examination, x-ray, and histopathology revealed that the patients suffered from a metastatic lesion, primary tumor being an adenocarcinoma of the breast diagnosed at the same time.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Dental Implants. Gingival Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535335.001).
  • [ISSN] 1523-0899
  • [Journal-full-title] Clinical implant dentistry and related research
  • [ISO-abbreviation] Clin Implant Dent Relat Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Dental Implants
  •  go-up   go-down


11. Heinroth S, Bilkenroth U, Eckert AW, Maurer P: [Bone metastases in the maxilla as first manifestation of renal cell cancer. A case report]. Mund Kiefer Gesichtschir; 2006 Jan;10(1):42-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bone metastases in the upper jaw are relatively rare but not unusual in oral and maxillofacial surgery.
  • CASE REPORT: We describe a 53-year-old female patient who suffered from a tumor in the oral cavity.
  • The first histological and clinical diagnosis revealed a granuloma pyogenicum.
  • Diagnostic procedures detected an adenocarcinoma of the left kidney with pelvic metastases.
  • CONCLUSION: The present case report demonstrates how difficult it can be to provide the right pathological diagnosis in biopsy material even regarding obvious malignancy.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / diagnosis. Maxillary Neoplasms / secondary
  • [MeSH-minor] Biopsy, Fine-Needle. Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Combined Modality Therapy. Diagnosis, Differential. Disease Progression. Female. Humans. Kidney / pathology. Maxilla / pathology. Middle Aged. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / secondary. Pelvic Neoplasms / therapy

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402238.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Malhotra G, Nair N, Awasare S: F-18 FDG PET scan findings in a case of carcinoma of the breast with a rare site of metastases to the gingival region. Clin Nucl Med; 2006 Dec;31(12):820-1
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is rare to find a metastasis to the oral region from a primary in the breast, but when this does occur, it usually involves the jawbones rather than the soft tissues.
  • She presented after 2 years with an exophytic growth in the upper alveolar region of the oral cavity.
  • Biopsy indicated gingival metastasis from a poorly differentiated adenocarcinoma of the breast.
  • The present case demonstrates a rare site of metastasis in the oral region from carcinoma of the breast.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Gingival Neoplasms / radionuclide imaging. Gingival Neoplasms / secondary. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117085.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Jayaprakash V, Natarajan KK, Moysich KB, Rigual NR, Ramnath N, Natarajan N, Reid ME: Wood dust exposure and the risk of upper aero-digestive and respiratory cancers in males. Occup Environ Med; 2008 Oct;65(10):647-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In a hospital-based case-control study conducted at Roswell Park Cancer Institute, Buffalo, NY, USA, an examination was carried out to determine the effect of self-reported WD exposure on 1522 male UADR cancer cases (241 oral and oropharyngeal, 90 nasal cavity, nasopharyngeal and hypopharyngeal, 124 laryngeal, 809 lung and tracheal and 258 oesophagus and gastric cardia) and 1522 male controls, frequency matched on age and smoking history.
  • WD was associated with an 82-93% increased risk of squamous cell, small cell and adenocarcinoma of the lung and more than twice the risk of developing squamous cell carcinoma of the nasal cavity, nasopharynx and hypopharynx, with a significant dose-response relationship.
  • Oral and oropharyngeal cancers showed a non-significant increase in risk.
  • CONCLUSION: WD exposure is a potential risk factor for UADR cancers, especially for cancers of the nasal cavity, nasopharynx, larynx and lung.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182588.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dust
  •  go-up   go-down


14. McNulty JP Md Facp Faahpm: Levorphanol for excruciating pain from oral cancer: a case report. Int J Pharm Compd; 2007 May-Jun;11(3):212-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levorphanol for excruciating pain from oral cancer: a case report.
  • In the United States the most common cancers of the head and neck are those of the oral cavity and pharynx.
  • In 2007, oral cancer will be diganosed in more than 37,000 Americans and will claim more than 7,500 lives.
  • The report presented here describes a case of extrarodinary pain in a woman with metastatic adenocarcinoma of the hard palate.
  • Her analgesic treatment consisted of opioids prescribed in increasingly higher doses until they were ineffective, the effects of treatment could not be tolerated, or she could not swallow the quantity or oral medication needed to provide relief.
  • Only the opioid levorphanol has provided effective analgesia with few adverse effects, and the patient's malignant pain is manageable with far fewer doses of oral medication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23996023.001).
  • [ISSN] 1092-4221
  • [Journal-full-title] International journal of pharmaceutical compounding
  • [ISO-abbreviation] Int J Pharm Compd
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Lutz JC, El-Bouihi M, Vidal N, Fricain JC, Robert M, Deminière C, Zwetyenga N: Mandibular metastases from an ileum stromal tumor. Rev Stomatol Chir Maxillofac; 2008 Dec;109(6):399-402
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Metastatic disease of the jaws is unusual and accounts for 1 to 4% of oral cavity malignancies.
  • Jaw metastases from the gastrointestinal (GI) tract usually evolve from adenocarcinoma of the esophagus, colon, and rectum.
  • The oral mucosa was macroscopically normal.
  • The patient was treated with imatinib but died 11 months after the diagnosis.
  • DISCUSSION: The prevalence of GIST is low but the true incidence may be higher because of under-diagnosis.
  • GIST should be included in the differential diagnosis of intramandibular tumor in patients with prior or current non-oral malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010506.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


16. Das A, Thomas S, Zablotska LB, Neugut AI, Chak A: Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol; 2006 May-Jun;40(5):405-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of esophageal adenocarcinoma with other subsequent primary cancers.
  • PURPOSE: Esophageal adenocarcinoma shares risk factors such as obesity and smoking with other common cancers.
  • The association of esophageal adenocarcinoma with other primary cancers has not been systematically evaluated.
  • The authors used the Surveillance, Epidemiology and End-Results database of the National Cancer Institute to explore the association of esophageal adenocarcinoma with other primary cancers.
  • PATIENTS AND METHODS: All adult patients with esophageal cancers, both adenocarcinoma and squamous cell carcinoma diagnosed between 1973 and 2001, were identified from the Surveillance, Epidemiology, and End-Results database, and standardized incidence rates were calculated for all subsequent primary cancers in these patients.
  • RESULTS: In comparison with a standard population, patients with esophageal adenocarcinoma were at higher risk for the development of another subsequent cancer, specifically, cancers of the oral cavity and pharynx, lung and bronchus, and kidney and renal pelvis, and adenocarcinoma of the colon/rectum and pancreas.
  • With squamous cell esophageal cancer, there was an association with tobacco-related cancers such as those of the oral cavity and pharynx, the lung and bronchus, and the breast.
  • There was either no association or even a negative association of esophageal adenocarcinoma with other obesity-related cancers such as breast, uterine, and prostate cancers.
  • CONCLUSIONS: Patients with esophageal adenocarcinoma and squamous cell carcinoma are at increased risk for the development of specific second primary cancers that share smoking as a common risk factor.
  • Esophageal adenocarcinoma does not have a strong association with obesity-related cancers with respect to the relative risk for the development of subsequent primary cancers.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Neoplasms, Second Primary / pathology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721221.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA89155; United States / NIDDK NIH HHS / DK / K24 DK028000
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


17. Mücke T, Robitzky LK, Kesting MR, Wagenpfeil S, Holhweg-Majert B, Wolff KD, Hölzle F: Advanced malignant minor salivary glands tumors of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jul;108(1):81-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant minor salivary glands tumors of the oral cavity.
  • STUDY DESIGN: From 1992 to 2006, a total of 95 patients with MSGC originating in the oral cavity were analyzed by univariate and multivariate analysis using the log-rank test and Cox-regression.
  • More studies are necessary to confirm prognostic factors and determine the true frequency of MSGC in the oral cavity.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Mucoepidermoid / epidemiology. Carcinoma, Mucoepidermoid / secondary. Disease-Free Survival. Female. Follow-Up Studies. Germany / epidemiology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Palatal Neoplasms / epidemiology. Prognosis. Retrospective Studies. Salvage Therapy. Sex Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386516.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Adelson RT, DeFatta RJ, Miles BA, Hoblitt SL, Ducic Y: Metastatic breast cancer of the oral cavity. Am J Otolaryngol; 2005 Jul-Aug;26(4):279-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast cancer of the oral cavity.
  • OBJECTIVE: To present a rare case of breast carcinoma initially presenting as an oral cavity mass.
  • CONCLUSIONS: Metastatic disease to the oral cavity represents only 1% of all oral cavity malignancies.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Mouth Neoplasms / secondary


19. Wahid A, Ahmad S, Sajjad M: Pattern of carcinoma of oral cavity reporting at dental department of Ayub medical college. J Ayub Med Coll Abbottabad; 2005 Jan-Mar;17(1):65-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of carcinoma of oral cavity reporting at dental department of Ayub medical college.
  • BACKGROUND: Carcinoma of oral cavity is amongst the first ten commonest malignancies in Pakistan.
  • Here we present a report of oral cancers received in this center over a period of 10 years.
  • METHODDS: This clinicopathological study consists of cases of carcinoma of oral cavity presenting to dentistry department of Ayub Medical College Abbottabad during 1993-2003.
  • The other 6 % lesions were histologically diagnosed as malignant melanoma, adenocarcinoma and acinar cell carcinoma.
  • [MeSH-major] Mouth Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929532.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


20. Kakarala K, Bhattacharyya N: Survival in oral cavity minor salivary gland carcinoma. Otolaryngol Head Neck Surg; 2010 Jul;143(1):122-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in oral cavity minor salivary gland carcinoma.
  • OBJECTIVE: To describe the epidemiology and comparative survival for minor salivary gland cancer of the oral cavity.
  • SUBJECTS AND METHODS: Cases of minor salivary gland cancer of the oral cavity were extracted from the Surveillance, Epidemiology, and End Results database (1988-2005) and staged.
  • RESULTS: A total of 639 salivary gland cancers of the oral cavity (55% female; mean age, 56 years) were identified with complete staging information, consisting of 318 mucoepidermoid, 169 adenoid cystic, 139 adenocarcinoma, and 14 acinic cell cancers.
  • Overall mean survival (months) was 157.9 and was similar across histologic subtypes: mucoepidermoid (172.4), adenoid cystic (141.4), acinic cell (138.7), and adenocarcinoma (147.2).
  • CONCLUSION: T stage and N stage are the most powerful predictors of survival in minor salivary gland carcinoma of the oral cavity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20620630.001).
  • [ISSN] 1097-6817
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ariyoshi Y, Miyatake S, Kimura Y, Shimahara T, Kawabata S, Nagata K, Suzuki M, Maruhashi A, Ono K, Shimahara M: Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep; 2007 Oct;18(4):861-6
Hazardous Substances Data Bank. BORON COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis.
  • The purpose of this clinical trial was to evaluate the utility of boron neutron capture therapy (BNCT) using epithermal neutrons for cases of recurrent cancer in the oral cavity, which are not indicated for a conventional treatment modality.
  • Mild malaise, oral mucositis and alopecia were seen as mild adverse effects; however, no life-threatening systemic symptoms were observed in any of the cases.
  • Our results suggested that BNCT is a useful treatment modality for recurrent or regionally metastasized oral cancer.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Neutrons
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Boron Compounds / therapeutic use. Carcinoma, Mucoepidermoid / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Head and Neck Neoplasms / radiotherapy. Humans. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786347.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Boron Compounds
  •  go-up   go-down


22. Pozzi EC, Altermatt HJ, Rees TD, Bornstein MM: Exophytic mass of the gingiva as the first manifestation of metastatic pulmonary adenocarcinoma. J Periodontol; 2008 Jan;79(1):187-91
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic mass of the gingiva as the first manifestation of metastatic pulmonary adenocarcinoma.
  • BACKGROUND: Metastasis of a malignant tumor to the oral cavity is rare, but it can be the first manifestation of a primary tumor.
  • METHODS: The clinicopathologic features of a gingival metastasis originating from lung adenocarcinoma in a female patient are described.
  • Finally, a biopsy of the lungs confirmed a poorly differentiated adenocarcinoma with multiple metastases, including the oral cavity.
  • CONCLUSIONS: An exophytic lesion on the gingiva can be the first sign of metastatic adenocarcinoma to the oral mucosa.
  • [MeSH-major] Adenocarcinoma / secondary. Gingival Neoplasms / secondary. Lung Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Fatal Outcome. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-7 / analysis. Mandible. Middle Aged. Nuclear Proteins / analysis. Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166110.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


23. Pintor MF, Figueroa L, Martínez B: Polymorphous low grade adenocarcinoma: review and case report. Med Oral Patol Oral Cir Bucal; 2007 Dec;12(8):E549-51
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low grade adenocarcinoma: review and case report.
  • Polymorphous Low-Grade Adenocarcinoma is a rare, malignant salivary gland tumor, which is found almost exclusively in minor salivary glands.
  • It is usually located in the hard or soft palate, although it may be found in the rest of the oral cavity too.
  • An incisional biopsy was carried out, and once the polymorphous low-grade adenocarcinoma diagnosis had been stated, the patient was sent to the Head and Neck Surgery Service of the Military Hospital, where the lesion was treated by wide surgical excision followed by radiation therapy.
  • [MeSH-major] Adenocarcinoma. Salivary Gland Neoplasms

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059236.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


24. Salgarelli AC, Cangiano A, Broccaioli EA, Collini M: Temporal myofascial flap in reconstructive surgery of the oral cavity. Minerva Stomatol; 2006 May;55(5):281-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal myofascial flap in reconstructive surgery of the oral cavity.
  • [MeSH-major] Carcinoma / surgery. Facial Muscles / surgery. Facial Neoplasms / surgery. Mouth Neoplasms / surgery. Oral Surgical Procedures / methods. Surgical Flaps
  • [MeSH-minor] Adenocarcinoma / surgery. Humans. Maxillary Neoplasms / surgery. Orbit Evisceration. Orbital Neoplasms / surgery. Parotid Neoplasms / surgery. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16688104.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng; ita
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Tincani AJ, Altemani A, Martins AS, Barreto G, Valério JB, Del Negro A, Araújo PP: Polymorphous low-grade adenocarcinoma at the base of the tongue: an unusual location. Ear Nose Throat J; 2005 Dec;84(12):794-5, 799
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low-grade adenocarcinoma at the base of the tongue: an unusual location.
  • Polymorphous low-grade adenocarcinoma (PLGA) is a malignant neoplasm of low aggressiveness that occurs almost exclusively in the minor salivary glands, primarily those in the palate.
  • The tumor was resected through the oral cavity with wide margins and dissection.
  • [MeSH-major] Adenocarcinoma / pathology. Tongue Neoplasms / pathology

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408562.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Li YJ, Tsai YC, Chen YC, Christiani DC: Human papilloma virus and female lung adenocarcinoma. Semin Oncol; 2009 Dec;36(6):542-52
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papilloma virus and female lung adenocarcinoma.
  • Lung cancer is the leading cause of cancer among women worldwide, and adenocarcinoma is the most common histological subtype among non-smoking women.
  • Previous studies showed that human papillomavirus (HPV) infection may relate to the tumorigenesis of pulmonary adenocarcinoma.
  • The second transmission route is the HPV infection of oral cavity resulting from dangerous sexual contacts, and subsequently transmitted to the lung.
  • Future studies are needed to demonstrate the causal inference between HPV infection and the risk of female lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Lung Neoplasms / virology. Papillomavirus Infections / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995646.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


27. Selim AA, Shaheen S, Lockshin N, Khachemoune A: Cutaneous metastasis of uterine adenocarcinoma: a case report and review of the literature. Cutis; 2009 Jul;84(1):33-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of uterine adenocarcinoma: a case report and review of the literature.
  • Cutaneous metastases from cancer are relatively uncommon in clinical practice but when present may herald the diagnosis of internal malignancy.
  • The most common sources of primary cancer are the breasts, lungs, large bowel, oral cavity, kidneys, stomach, ovaries, and malignant melanoma.
  • Despite the high incidence of uterine adenocarcinoma, cutaneous metastases are uncommon.
  • The diagnosis of cutaneous metastatic carcinoma hinges on histopathologic evaluation of the involved skin.
  • We discuss and review the diagnosis and management of cutaneous metastasis of uterine adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Skin Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19743722.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Pires FR, Azevedo RS, Ficarra G, Cardoso AS, Carlos R, Kowalski LP, de Almeida OP: Metastatic renal cell carcinoma to the oral cavity and clear cell mucoepidermoid carcinoma: comparative clinicopathologic and immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):e22-7
Hazardous Substances Data Bank. Carminic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic renal cell carcinoma to the oral cavity and clear cell mucoepidermoid carcinoma: comparative clinicopathologic and immunohistochemical study.
  • BACKGROUND: Metastatic clear cell renal cell carcinoma (CCRCC) should be considered in differential diagnosis of intraoral clear cell tumors, including mucoepidermoid carcinoma (MEC).
  • OBJECTIVE AND STUDY DESIGN: We compared the clinical, histologic, histochemical, and immunohistochemical characteristics of 9 oral metastatic CCRCCs and 8 intraoral clear cell MECs.
  • RESULTS: Oral metastatic CCRCC affected salivary-gland containing tissues in 7 cases (78%).
  • Microscopically, oral metastasis revealed a proliferation of neoplastic clear cells arranged in an alveolar pattern with central blood vessels, features that were not seen in any intraoral clear cell MEC.
  • Immunohistochemistry showed similarities in cytokeratin expression; vimentin and CD10 were expressed in all oral metastatic CCRCCs but in only 1 clear cell MEC each.
  • CONCLUSIONS: Besides clinical history, the alveolar pattern, vessel distribution, absence of mucicarmine staining, and vimentin and CD10 immunoexpression are useful in histologic differential diagnosis of CCRCC and clear cell MEC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Renal Cell / secondary. Mouth Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carmine. Cell Nucleus / ultrastructure. Coloring Agents. Cytoplasm / ultrastructure. Diagnosis, Differential. Female. Hemorrhage / pathology. Histocytochemistry. Humans. Immunohistochemistry. Keratins / analysis. Male. Microvessels / pathology. Middle Aged. Neprilysin / analysis. Salivary Gland Neoplasms / blood supply. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / secondary. Vimentin / analysis

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20303042.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Vimentin; 51395-97-2 / mucicarmine; 68238-35-7 / Keratins; CID8Z8N95N / Carmine; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


29. Bingle L, Cross SS, High AS, Wallace WA, Rassl D, Yuan G, Hellstrom I, Campos MA, Bingle CD: WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res; 2006;7:61
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung.
  • CONCLUSION: We believe that these studies support the hypothesis that WFDC2 may be a component of the innate immune defences of the lung, nasal and oral cavities and suggest that WFDC2 functions in concert with related WAP domain containing proteins in epithelial host defence.
  • [MeSH-major] Adenocarcinoma / immunology. Epididymal Secretory Proteins / physiology. Lung Neoplasms / immunology. Mouth / immunology. Proteins / physiology. Respiratory System / immunology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):267-77 [16061277.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):22136-46 [10766760.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 2;1493(3):363-7 [11018263.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1147-53 [11017147.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Jul;25(1):84-91 [11472979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Mol Hum Reprod. 2002 Apr;8(4):341-9 [11912282.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2768-73 [11965550.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):98-102 [12023833.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):116-20 [12023837.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Oct;27(4):436-45 [12356577.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1249-56 [12437112.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Feb;30(2):184-92 [12920053.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):811-9 [14990636.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1982 May-Jun;91(3 Pt 1):268-71 [7046595.001]
  • [Cites] Environ Health Perspect. 1990 Apr;85:71-80 [2384069.001]
  • [Cites] Biol Reprod. 1991 Aug;45(2):350-7 [1686187.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1993 Jun;29A(6):481-92 [7687243.001]
  • [Cites] Biochem J. 1996 Jun 15;316 ( Pt 3):967-75 [8670177.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):1092-8 [8887613.001]
  • [Cites] Infect Immun. 1996 Nov;64(11):4520-4 [8890201.001]
  • [Cites] Cell. 1997 Feb 7;88(3):417-26 [9039268.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1141-9 [9242546.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1235-40 [9351627.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 18;241(2):305-11 [9425267.001]
  • [Cites] Gene. 1999 Mar 18;229(1-2):101-8 [10095109.001]
  • [Cites] Biochem J. 1999 Jun 15;340 ( Pt 3):569-77 [10359639.001]
  • [Cites] FEBS Lett. 1999 Jun 11;452(3):309-13 [10386612.001]
  • [Cites] Eur Respir J. 1999 May;13(5):1029-36 [10414400.001]
  • [Cites] Infect Immun. 1999 Sep;67(9):4485-9 [10456890.001]
  • [Cites] J Pathol. 2005 Mar;205(4):491-7 [15685591.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2162-9 [15781627.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 May;32(5):443-52 [15668324.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Oct;289(4):L545-53 [15937068.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1251-64 [15951573.001]
  • [Cites] J Mol Graph Model. 1999 Apr;17(2):106-13, 134-6 [10680116.001]
  • (PMID = 16600032.001).
  • [ISSN] 1465-993X
  • [Journal-full-title] Respiratory research
  • [ISO-abbreviation] Respir. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Epididymal Secretory Proteins; 0 / Proteins; 0 / WFDC2 protein, human
  • [Other-IDs] NLM/ PMC1459147
  •  go-up   go-down


30. Wang H, Yao J, Solomon M, Axiotis CA: Sebaceous carcinoma of the oral cavity: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Aug;110(2):e37-40
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sebaceous carcinoma of the oral cavity: a case report and review of the literature.
  • We discuss the differential diagnosis and histogenesis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Mouth Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20659693.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen
  •  go-up   go-down


31. Sánchez-Jiménez J, Acebal-Blanco F, Arévalo-Arévalo RE, Molina-Martínez M: Metastatic tumours in upper maxillary bone of esophageal adenocarcinoma. A case report. Med Oral Patol Oral Cir Bucal; 2005 May-Jul;10(3):252-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumours in upper maxillary bone of esophageal adenocarcinoma. A case report.
  • Metastases in the oral cavity are rare lesions which represent approximately 1% of all malignant neoplasms in the oral cavity.
  • Oral metastases are located in the mandible 80-90% on average, the maxilla location being rarer.
  • Metastases in mouth soft tissue are also rare, and within these it is on the gums where they more frequently occur.
  • Primary tumours which metastasize to mouth are most commonly: lung, breast and kidney.
  • Oral cavity metastases appear as a result of distant disease spreading and show wrong prognosis, with short survival.
  • Here we present a clinical case of a patient diagnosed with esophagus adenocarcinoma which presented metastasis in upper-left maxillary bone.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Maxillary Neoplasms / secondary. Maxillary Sinus Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876970.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


32. Storck K, Hadi UM, Simpson R, Ramer M, Brandwein-Gensler M: Sinonasal renal cell-like adenocarcinoma: a report on four patients. Head Neck Pathol; 2008 Jun;2(2):75-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal renal cell-like adenocarcinoma: a report on four patients.
  • BACKGROUND: We have described an unusual sinonasal neoplasm which is a histological mimic of renal cell carcinoma (RCC) and coined the nosological classification "sinonasal renal cell-like adenocarcinoma" (SRCLA) to describe this unusual entity.
  • Three tumors were in the nasal cavity and one was in the nasopharynx.
  • All patients are disease-free, based on endoscopy and/or radiography, 2, 4, 5 and 8 years after diagnosis.
  • CONCLUSION: Sinonasal renal cell-like adenocarcinoma is a rare and distinct entity noteworthy in its resemblance to RCC.
  • [MeSH-major] Adenocarcinoma / pathology. Nasal Cavity / pathology. Nasopharyngeal Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Kidney Neoplasms / pathology. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Pathol Microbiol. 2003 Jan;46(1):93-5 [15027741.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):835-45 [11420454.001]
  • [Cites] Histopathology. 2008 Jan;52(2):158-66 [18036175.001]
  • [Cites] Ear Nose Throat J. 2001 Jul;80(7):462-7 [11480304.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Apr;128(4):441-7 [11926922.001]
  • [Cites] Rhinology. 2002 Mar;40(1):44-7 [12012954.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):519-22 [12199168.001]
  • [Cites] Am J Otolaryngol. 2004 Jul-Aug;25(4):255-7 [15239032.001]
  • [Cites] Laryngoscope. 1973 Sep;83(9):1527-39 [4758761.001]
  • [Cites] Mt Sinai J Med. 1988 Oct;55(5):417-20 [3265187.001]
  • [Cites] Urol Int. 2004;73(3):285-6 [15539854.001]
  • [Cites] Oral Oncol. 2005 Jan;41(1):3-10 [15598579.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Jan;262(1):69-71 [14986018.001]
  • [Cites] Surg Today. 2005;35(4):300-3 [15815846.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1097-100 [15933529.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):347-52 [16280664.001]
  • [Cites] Acta Cytol. 2005 Sep-Oct;49(5):543-8 [16334034.001]
  • [Cites] Urology. 2006 Jan;67(1):199 [16413368.001]
  • [Cites] Oral Dis. 2006 Jul;12(4):364-70 [16792720.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):464 [10699832.001]
  • (PMID = 20614326.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2807555
  • [Keywords] NOTNLM ; Renal cell carcinoma / Renal cell-like carcinoma / Sinonasal / Vermeer
  •  go-up   go-down


33. Fukui D, Bando G, Ishikawa Y, Kadota K: Adenosquamous carcinoma with cilium formation, mucin production and keratinization in the nasal cavity of a red fox (Vulpes vulpes schrencki). J Comp Pathol; 2007 Aug-Oct;137(2-3):142-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma with cilium formation, mucin production and keratinization in the nasal cavity of a red fox (Vulpes vulpes schrencki).
  • A diagnosis of adenosquamous carcinoma was made in an 11-year-old red fox.
  • The nasal and oral lesions were composed of adenocarcinomatous cells and squamous cells, the latter predominating in the oral lesions.
  • Although inconspicuous in the oral cavity and marrow, ciliated cells with or without mucin were observed in the adenocarcinomatous and cystic elements.
  • Neoplastic basal cells and less-differentiated adenocarcinoma cells, which were identifiable by immunolabelling for cytokeratin 5 (CK5) and CK18, were considered to be pluripotential.
  • [MeSH-minor] Animals. Bone Marrow / pathology. Keratin-18 / metabolism. Keratin-5 / metabolism. Nasal Cavity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645890.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-18; 0 / Keratin-5; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


34. Negahban S, Daneshbod Y, Khademi B, Rasekhi AR, Soleimanpour H: Sinonasal clear cell adenocarcinoma: a case report. Acta Cytol; 2009 Sep-Oct;53(5):597-600

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal clear cell adenocarcinoma: a case report.
  • We present cytologic findings of clear cell sinonasal adenocarcinoma and related pitfalls.
  • Computed tomography was performed, revealing an expansile mass involving the nasal cavity, left maxillary sinus, ethmoid sinus with extension to sphenoid sinus, left side of oral cavity and left orbit.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Nasal Mucosa / pathology. Paranasal Sinus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19798893.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Canjuga I, Mravak-Stipetić M, Kopić V, Galić J: Oral acanthosis nigricans: case report and comparison with literature reports. Acta Dermatovenerol Croat; 2008;16(2):91-5
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral acanthosis nigricans: case report and comparison with literature reports.
  • Acanthosis nigricans (AN) is a rare condition which may affect oral cavity.
  • Malignant AN is most often associated with gastric adenocarcinoma but cancers of other sites and types may also occur.
  • Oral lesions occurred after the tumor had been diagnosed, i.e. after third operation for tumor recurrence.
  • The fifth operation for tumor recurrence resulted in slight improvement of oral changes.
  • It is concluded that the severity of oral changes is in correlation with tumor progression.
  • The occurrence of oral lesions may be an indicator of tumor progression.
  • [MeSH-major] Acanthosis Nigricans / etiology. Acanthosis Nigricans / pathology. Carcinoma, Transitional Cell / complications. Mouth Diseases / etiology. Mouth Diseases / pathology. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541106.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 20
  •  go-up   go-down


36. Bhutani M, Pathak AK, Fan YH, Liu DD, Lee JJ, Tang H, Kurie JM, Morice RC, Kim ES, Hong WK, Mao L: Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila); 2008 Jun;1(1):39-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs.
  • The lungs and oral cavity of smokers are exposed to tobacco carcinogens.
  • We hypothesized that tobacco-induced molecular alterations in the oral epithelium are similar to those in the lungs, and thus the oral epithelium may be used as a surrogate tissue for assessing alterations in the lungs.
  • We used methylation-specific PCR to analyze promoter methylation of the p16 and FHIT genes at baseline and 3 months after intervention in 1,774 oral and bronchial brush specimens from 127 smokers enrolled in a randomized placebo-controlled chemoprevention trial.
  • The association between methylation patterns in oral tissues and bronchial methylation indices (methylated sites / total sites per subject) was analyzed in a blinded fashion.
  • At baseline, promoter methylation in bronchial tissue was present in 23% of samples for p16, 17% for FHIT, and 35% for p16 and FHIT; these percentages were comparable to methylation in oral tissue: 19% (p16), 15% (FHIT), and 31% (p16 and FHIT).
  • Data from both oral and bronchial tissues were available for 125 individuals, in whom the two sites correlated strongly with respect to alterations (P < 0.0001 for both p16 and FHIT).
  • At baseline, the mean bronchial methylation index was far higher in patients with oral tissue methylation (in either of the two genes; 39 patients) than in patients without oral tissue methylation (86 patients): 0.53 +/- 0.29 versus 0.27 + 0.26 methylation index (P < 0.0001).
  • Our results support the potential of oral epithelium as a surrogate tissue for assessing tobacco-induced molecular damage in the lungs and thus have important implications for designing future lung cancer prevention trials and for research into the risk and early detection of lung cancer.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Prev Res (Phila). 2008 Jun;1(1):12-4 [19138931.001]
  • (PMID = 19138934.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA091844; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / CA091844
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ NIHMS630678; NLM/ PMC4183362
  •  go-up   go-down


37. Kleinschmidt S, Puff C, Baumgärtner W: Metastasizing oral squamous cell carcinoma in an aged pig. Vet Pathol; 2006 Jul;43(4):569-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing oral squamous cell carcinoma in an aged pig.
  • Clinical examination revealed a mass in the left part of the oral cavity extending from the hard to the soft palate.
  • Additional findings included a uterine adenocarcinoma, a hepatocellular adenoma, and nodular hyperplasias in spleen and adrenal glands.
  • Histologically, the poorly demarcated, infiltrative growing oral mass consisted of islands, cords, and single epithelial cells with moderate squamous differentiation.
  • The present findings represent the first report of a metastasizing oral squamous cell carcinoma in a pig.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Mouth Neoplasms / veterinary. Swine Diseases / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847003.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


38. Loh KS, Barker E, Bruch G, O'Sullivan B, Brown DH, Goldstein DP, Gilbert RW, Gullane PJ, Irish JC: Prognostic factors in malignancy of the minor salivary glands. Head Neck; 2009 Jan;31(1):58-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Adenoid cystic carcinoma (46.8%), mucoepidermoid carcinoma (22.8%), and adenocarcinoma (18.7%) were the most common pathologies.
  • The most frequent sites of primary tumor were in the oral cavity (44.4%) and nasal cavity (40.4%).
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Mucoepidermoid / mortality. Salivary Gland Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Mouth / pathology. Multivariate Analysis. Nasal Cavity / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Salivary Glands, Minor / pathology. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc. Head Neck, 2009.
  • (PMID = 18853449.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Murdoch WJ: Carcinogenic potential of ovulatory genotoxicity. Biol Reprod; 2005 Oct;73(4):586-90
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact, the majority of cancers of the ovary are derived from the surface epithelium; and circumstances that avert ovulation (oral contraceptive use, pregnancy/lactation) protect against ovarian adenocarcinoma.
  • Ovarian cancer of surface epithelial origin is a deadly insidious disease because it characteristically remains asymptomatic until it has metastasized throughout the abdominal cavity; therefore, prevention is a high priority.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adenocarcinoma / prevention & control. Animals. Contraceptive Agents, Female / pharmacology. DNA Damage. Epithelial Cells / pathology. Female. Humans. Lactation. Oxidative Stress. Pregnancy. Progesterone / metabolism. Vitamin E / pharmacology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958727.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-97796; United States / NCRR NIH HHS / RR / RR-016474
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 1406-18-4 / Vitamin E; 4G7DS2Q64Y / Progesterone
  • [Number-of-references] 103
  •  go-up   go-down


40. Kruse AL, Luebbers HT, Obwegeser JA, Edelmann L, Graetz KW: Temporomandibular disorders associated with metastases to the temporomandibular joint: a review of the literature and 3 additional cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Aug;110(2):e21-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Metastases involving the oral cavity account for 1% to 8% of all malignancies in the oral cavity Involvement of the temporomandibular joint (TMJ) is uncommon.
  • Adenocarcinoma was predominant (72.97%).
  • CONCLUSION: Establishing an exact diagnosis of metastatic lesions in the TMJ can provide a diagnostic challenge.
  • Clinicians should include the suspicion of cancer in the differential diagnosis, in particular when patients have a previous history of malignant neoplasm or do not respond to treatment appropriately.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma / secondary. Mandibular Condyle / pathology. Mandibular Neoplasms / secondary. Temporomandibular Joint Disorders / etiology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Temporomandibular Joint Dysfunction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20659692.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


41. Nicolai G, Lorè B, Prucher G, De Marinis L, Calabrese L: Treatment of N in the upper maxillary tumors. J Craniofac Surg; 2010 Nov;21(6):1798-800

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell carcinoma of the maxilla extending to the oral cavity (T1-T2) shows a higher laterocervical lymphophily than the superoposterior ones (T3-T4).
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Gingival Neoplasms / pathology. Humans. Lymphatic Metastasis / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Palatal Neoplasms / pathology. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119424.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Ahmed Z, Azad NS, Rauf F, Yaqoob N, Husain A, Ahsan A, Ahmed R, Kayani N, Pervez S, Hassan SH: Frequency of primary solid malignant neoplasms in different age groups as seen in our practice. J Ayub Med Coll Abbottabad; 2007 Jul-Sep;19(3):56-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the third decade, colorectal adenocarcinoma in males and infiltrating.
  • In the fourth decade, squamous cell carcinoma of oral cavity in males and infiltrating ductal carcinoma of breast in females.
  • In the fifth decade squamous cell carcinoma of oral cavity in males and infiltrating ductal carcinoma of breast in females.
  • In sixth decade, squamous cell carcinoma of oral cavity in males and infiltrating ductal carcinoma of breast in females and in the seventh decade, prostatic adenocarcinoma in males and infiltrating ductal carcinoma of the breast in females.
  • Above age of 70 years, the commonest malignant were again prostatic adenocarcinoma in males and infiltrating ductal carcinoma of breast in females.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adolescent. Adult. Age Distribution. Aged. Breast Neoplasms / epidemiology. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Squamous Cell / epidemiology. Child. Colorectal Neoplasms / epidemiology. Female. Hodgkin Disease / epidemiology. Humans. Kidney Neoplasms / epidemiology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Osteosarcoma / epidemiology. Pakistan / epidemiology. Retrospective Studies. Sarcoma, Ewing / epidemiology. Wilms Tumor / epidemiology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444593.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


43. Wu IC, Wu DC, Yu FJ, Wang JY, Kuo CH, Yang SF, Wang CL, Wu MT: Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol; 2009 Nov 21;15(43):5465-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In total, 199 oral squamous-cell carcinoma (SCC), 317 esophageal SCC, 196 gastric cardia and non-cardia adenocarcinoma and 240 colon adenocarcinoma patients were recruited for serum tests of H pylori infection.
  • RESULTS: Presence of H pylori infection was significantly inversely associated with esophageal SCC [adjusted odds ratio (AOR): 0.315-0.472, all P-value < 0.05] but positively associated with gastric adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060, all P-value < 0.05) in comparison to the three control groups.
  • Similar results were not found in cancers of the oral cavity and colon.
  • CONCLUSION: Our findings support the finding that H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Carcinoma, Squamous Cell / microbiology. Cardia / microbiology. Esophageal Neoplasms / microbiology. Helicobacter Infections / blood. Helicobacter Infections / complications. Helicobacter pylori / immunology. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Invest. 2008 Oct;38(10):760-5 [18837801.001]
  • [Cites] Gut. 2008 Jun;57(6):727-33 [17895354.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):84-8 [11197293.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):226-33 [11158192.001]
  • [Cites] Int J Colorectal Dis. 2001 Aug;16(4):202-10 [11515678.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):658-60 [11531247.001]
  • [Cites] J Gastroenterol. 2002;37 Suppl 13:28-33 [12109662.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):68-76 [12559187.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):123-8 [12593607.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):129-34 [12593608.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1202-4 [14520446.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2789-93 [7773928.001]
  • [Cites] J Natl Cancer Inst. 1995 May 17;87(10):762-3 [7563155.001]
  • [Cites] Scand J Gastroenterol Suppl. 1995;212:13-8 [8578226.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1442-7 [9136820.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1316-21 [9260797.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):633-9 [9516382.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1271-6 [9707050.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):520-4 [10404065.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):621-4 [10428200.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):475-82 [15455377.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):761-7 [15688293.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):588-93 [15743356.001]
  • [Cites] Helicobacter. 2005 Aug;10(4):312-7 [16104947.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):200-7 [16754633.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1999-2000 [16708392.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2827-31 [17036331.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):172-6 [17179990.001]
  • [Cites] BMC Cancer. 2006;6:287 [17173682.001]
  • [Cites] Eur J Cancer. 2007 May;43(7):1188-99 [17383866.001]
  • [Cites] Scand J Gastroenterol. 2007 Aug;42(8):933-40 [17613922.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):387-94 [10685740.001]
  • (PMID = 19916178.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  • [Other-IDs] NLM/ PMC2778104
  •  go-up   go-down


44. Migliario M, Rimondini L, Valente G: Benign fibrous histiocytoma of the lower lip. J Craniofac Surg; 2010 Nov;21(6):2024-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To our knowledge, involvement of the soft tissue of the oral cavity is rare.
  • This rare tumor should be considered in the differential diagnosis of the oral soft-tissue neoplasms.
  • [MeSH-major] Histiocytoma, Benign Fibrous / diagnosis. Lip Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Diagnosis, Differential. Female. Giant Cells / pathology. Hemosiderin / analysis. Histiocytes / pathology. Humans. Lymphocytes / pathology. Middle Aged. Neoplasms, Second Primary / diagnosis. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119493.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9011-92-1 / Hemosiderin
  •  go-up   go-down


45. Doobaree IU, Landis SH, Linklater KM, El-Hariry I, Moller H, Tyczynski J: Head and neck cancer in South East England between 1995-1999 and 2000-2004: An estimation of incidence and distribution by site, stage and histological type. Oral Oncol; 2009 Sep;45(9):809-14
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The three commonest HNC sites were intra-oral cavity, larynx and tonsil.
  • Males were two to six times as likely as females to be diagnosed with HNC and there was a trend toward younger age at diagnosis over time.
  • Significant increases in the incidence rate of intra-oral cavity cancer for both sexes and tonsillar cancer among males were observed.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adolescent. Adult. Age Distribution. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Child. Child, Preschool. England / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Registries. Sex Distribution. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251472.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. Gomes CC, Lacerda JC, Pimenta FJ, do Carmo MA, Gomez RS: Intraoral sebaceous carcinoma. Eur Arch Otorhinolaryngol; 2007 Jul;264(7):829-32
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraoral sebaceous carcinoma (SC) is a rare tumour in the oral cavity thought to arise from malignant transformation of oral sebaceous glands.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Mouth Neoplasms / diagnosis. Sebaceous Gland Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Radiography, Panoramic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285332.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Villaret AB, Piazza C, Peretti G, Calabrese L, Ansarin M, Chiesa F, Pellini R, Spriano G, Nicolai P: Multicentric prospective study on the prevalence of sublevel IIb metastases in head and neck cancer. Arch Otolaryngol Head Neck Surg; 2007 Sep;133(9):897-903

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary site distribution included the following: oral cavity in 111 patients, larynx in 92, oropharynx in 32, thyroid gland in 22, skin of the lateral face or scalp in 16, hypopharynx in 11, unknown primary in 7, and parotid gland in 6.
  • Tumor histologic type in the sublevel IIB+ population was squamous cell carcinoma in 80%, papillary carcinoma in 8%, melanoma in 8%, and adenocarcinoma in 4%.
  • The chi(2) test showed a significantly higher risk for LN metastases at sublevel IIB in patients affected by parotid gland primary tumors (33%), tumors of the skin or scalp (25%), unknown primary tumors (14%), and cancers of the oral cavity (10%) (P = .02) and in those clinically staged as cN+ (P < .001).
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cross-Sectional Studies. Female. Humans. Lymph Node Excision. Male. Melanoma / epidemiology. Melanoma / pathology. Melanoma / surgery. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875856.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


48. Giri S, Poindexter KM, Sundar SN, Firestone GL: Arecoline induced disruption of expression and localization of the tight junctional protein ZO-1 is dependent on the HER 2 expression in human endometrial Ishikawa cells. BMC Cell Biol; 2010 Jul 06;11:53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Approximately 600 million people chew Betel nut, making this practice the fourth most popular oral habit in the world.
  • Arecoline, the major alkaloid present in betel nut is one of the causative agents for precancerous lesions and several cancers of mouth among those who chew betel nut.
  • However, few reports exist as to the effects of arecoline in human tissues other than oral cancer cell lines.
  • CONCLUSION: Arecoline is known to induce precancerous lesions and cancer in the oral cavity of betel nut users.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2000 Mar;11(3):849-62 [10712504.001]
  • [Cites] Biochem Pharmacol. 2007 Feb 15;73(4):561-73 [17123469.001]
  • [Cites] Oral Oncol. 2001 Sep;37(6):477-92 [11435174.001]
  • [Cites] Carcinogenesis. 2001 Sep;22(9):1527-35 [11532876.001]
  • [Cites] Rapid Commun Mass Spectrom. 2003;17(17):1958-64 [12913859.001]
  • [Cites] Br J Psychiatry. 1981 Jan;138:46-50 [7023592.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] Nature. 1986 Jan 16-22;319(6050):230-4 [3003577.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1986;51 Pt 2:977-82 [3472771.001]
  • [Cites] Mol Cell Biol. 1987 May;7(5):2019-23 [3299059.001]
  • [Cites] Oncogene. 1988 Mar;2(3):283-7 [3281095.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):4968-71 [2569928.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(5):285-90 [2570489.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):421-5 [1967224.001]
  • [Cites] Obstet Gynecol. 1990 Sep;76(3 Pt 1):381-7 [1974342.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3460-4 [2014265.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3296-303 [1674898.001]
  • [Cites] Cancer Lett. 1992 Aug 31;65(3):215-20 [1355405.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):21-5 [1356014.001]
  • [Cites] J Urol. 1993 Nov;150(5 Pt 1):1427-33 [8105108.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14661-5 [7514177.001]
  • [Cites] Biochim Biophys Acta. 1994 Dec 30;1198(2-3):165-84 [7819273.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(2-3):325-35 [7881109.001]
  • [Cites] Hum Pathol. 1995 Jun;26(6):601-6 [7774888.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10779-84 [8855257.001]
  • [Cites] Life Sci. 1997;61(11):1083-95 [9307054.001]
  • [Cites] J Cell Biol. 1997 Nov 3;139(3):785-95 [9348294.001]
  • [Cites] Biochim Biophys Acta. 1998 Feb 20;1377(1):M25-37 [9540810.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):3-9 [9815530.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1767-73 [9846967.001]
  • [Cites] Public Health. 1999 Jul;113(4):189-92 [10483082.001]
  • [Cites] Clin Oral Investig. 1999 Mar;3(1):25-9 [10522189.001]
  • [Cites] Cell Res. 2005 Jul;15(7):504-10 [16045813.001]
  • [Cites] Mol Endocrinol. 2007 Oct;21(10):2403-15 [17595317.001]
  • [Cites] Oral Oncol. 2008 Feb;44(2):180-6 [17418620.001]
  • [Cites] Drug Alcohol Depend. 2008 May 1;95(1-2):134-9 [18282667.001]
  • [Cites] J Formos Med Assoc. 2008 May;107(5):355-63 [18492619.001]
  • [Cites] Histochem Cell Biol. 2008 Jul;130(1):1-20 [18365233.001]
  • [Cites] Oral Oncol. 2008 Sep;44(9):884-90 [18234541.001]
  • [Cites] Bull World Health Organ. 2005 Sep;83(9):656-60 [16211156.001]
  • [Cites] Chem Res Toxicol. 2006 Jun;19(6):818-27 [16780361.001]
  • [Cites] Toxicology. 2006 Oct 3;227(1-2):94-104 [16945459.001]
  • [Cites] EMBO J. 2000 May 2;19(9):2024-33 [10790369.001]
  • (PMID = 20604955.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK042799-21; United States / NIDDK NIH HHS / DK / R01 DK042799; United States / NIDDK NIH HHS / DK / DK-42799; United States / NIDDK NIH HHS / DK / R01 DK042799-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein; 4ALN5933BH / Arecoline; 7S5I7G3JQL / Dexamethasone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2910664
  •  go-up   go-down


49. Mayr SI, Hafizovic K, Waldfahrer F, Iro H, Kütting B: Characterization of initial clinical symptoms and risk factors for sinonasal adenocarcinomas: results of a case-control study. Int Arch Occup Environ Health; 2010 Aug;83(6):631-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Sinonasal adenocarcinoma is a rare cancer, frequently associated with occupational exposure to inhalable wood dust.
  • Location and long latency make early diagnosis difficult.
  • METHODS: Of 58 patients, 31 diagnosed with sinonasal adenocarcinoma (cases) between 1973 and 2007 were identified and underwent standardized interview on clinical data.
  • A total of 85 patients diagnosed over the same period with carcinoma of the oral cavity served as controls.
  • RESULTS: The ethmoid was confirmed as the predominant site of adenocarcinoma associated with wood dust exposure, whereas the nasal cavity was most commonly affected in patients denying any exposure to wood dust.
  • The main initial clinical symptoms were nasal obstruction 6 months (71%) and epistaxis 4 years (41.9%) prior to diagnosis.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / physiopathology. Paranasal Sinus Neoplasms / epidemiology. Paranasal Sinus Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885670.001).
  • [ISSN] 1432-1246
  • [Journal-full-title] International archives of occupational and environmental health
  • [ISO-abbreviation] Int Arch Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dust
  •  go-up   go-down


50. Kuttan NA, Flemming DK, Dane JN, Ang DB: Metastatic lesion of the anterior mandible with an occult primary: a case report. Spec Care Dentist; 2006 Mar-Apr;26(2):76-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic tumors to the oral cavity are relatively uncommon and account for about 1% of all oral cancers.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Mandibular Neoplasms / secondary. Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681243.001).
  • [ISSN] 0275-1879
  • [Journal-full-title] Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry
  • [ISO-abbreviation] Spec Care Dentist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Lai G, Nemolato S, Lecca S, Parodo G, Medda C, Faa G: The role of immunohistochemistry in the diagnosis of hyalinizing clear cell carcinoma of the minor salivary gland: a case report. Eur J Histochem; 2008 Oct-Dec;52(4):251-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in the diagnosis of hyalinizing clear cell carcinoma of the minor salivary gland: a case report.
  • A case of hyalinizing clear cell carcinoma (HCCC) of the minor salivary glands of the oral cavity is reported.
  • These findings confirmed the diagnosis of HCCC of minor salivary glands of the oral cavity.
  • The clinical presentation, the immunohistochemical pattern and the role of cytokeratins in the differential diagnosis of HCCC are discussed with a review of the literature.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Immunohistochemistry / methods. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Diagnosis, Differential. Female. Humans. Hyalin / metabolism. Keratins / analysis. Melanoma / diagnosis. Melanoma / secondary. Middle Aged. Myoepithelioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109100.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


52. Mitsuya J, Hara H, Ito K, Ishii N, Hashimoto T, Terui T: Metastatic ovarian carcinoma-associated subepidermal blistering disease with autoantibodies to both the p200 dermal antigen and the gamma 2 subunit of laminin 5 showing unusual clinical features. Br J Dermatol; 2008 Jun;158(6):1354-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical features showed severe blisters and erosions on multiple mucous membranes (i.e. lip, oral cavity, nose, eye, genitalia and anus) and on both the periungual and subungual regions.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Antigens, Neoplasm / immunology. Autoantibodies / immunology. Blister / immunology. Epidermolysis Bullosa Acquisita / diagnosis. Laminin / immunology. Ovarian Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294311.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Immunoglobulin G; 0 / LAMC2 protein, human; 0 / Laminin; 0 / antigen p200
  •  go-up   go-down


53. Douglas JG, Goodkin R, Laramore GE: Gamma knife stereotactic radiosurgery for salivary gland neoplasms with base of skull invasion following neutron radiotherapy. Head Neck; 2008 Apr;30(4):492-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients had the following characteristics: median age: 54 years (range, 23-80); median follow-up period: 20.5 months (range, 4-55); women-to-men patient ratio: 1.1:1; histology: 29 adenoid cystic, 3 adenocarcinoma, 1 acinic cell, 1 mucoepidermoid; primary sites of disease: 6 nasopharyngeal, 14 paranasal sinuses, 4 parotid gland, 8 oral cavity, 1 lacrimal gland, and 1 auditory canal.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Radiotherapy Dosage. Skull Base / pathology. Skull Base / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023034.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Illanes D, Broman J, Meyer B, Kredentser D, McElrath T, Timmins P 3rd: Verrucous carcinoma of the endometrium: case history, pathologic findings, brief review of literature and discussion. Gynecol Oncol; 2006 Aug;102(2):375-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A defined disease of the oral cavity, larynx, esophagus, skin, vulva, vagina and cervix.
  • But a verrucous carcinoma arising from the endometrium without evidence of cervical malignancy or endometrial adenocarcinoma is extremely rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529798.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, Boterberg T, Willems P, Vral A, De Neve W, Thierens H: Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys; 2009 Mar 15;73(4):1187-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The mean dose (D(mean)) to the oral cavity and constrictor pharyngeus (PC) muscles was significantly associated with the development of mucositis and dysphagia, respectively.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Antigens, Nuclear / genetics. Arabidopsis Proteins / genetics. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / radiotherapy. DNA Ligases / genetics. DNA-Binding Proteins / genetics. Female. Humans. Male. Middle Aged. Mouth / radiation effects. Mouth Mucosa / radiation effects. Pharyngeal Muscles / radiation effects. Rad51 Recombinase / genetics. Radiodermatitis / genetics. Radiotherapy Dosage. Regression Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251090.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Arabidopsis Proteins; 0 / DNA-Binding Proteins; 0 / Ku autoantigen; 0 / X-ray repair cross complementing protein 3; EC 2.7.7.- / ATRAD51 protein, Arabidopsis; EC 2.7.7.- / Rad51 Recombinase; EC 6.5.1.- / DNA Ligases; EC 6.5.1.1 / DNA ligase (ATP)
  •  go-up   go-down


56. Suedmeyer WK, Johnson G: Survey of neoplasia in red kangaroos (Macropus rufus), 1992-2002, in a zoological collection. J Zoo Wildl Med; 2007 Jun;38(2):231-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two squamous cell carcinomas of the oral cavity, two mammary gland adenocarcinomas, a multicentric T-cell lymphosarcoma, and one submucosal pyloric lipoma were diagnosed in six of 28 kangaroo deaths.
  • On the basis of these cases and a review of the literature, the most commonly observed neoplasms in red kangaroos are mammary gland adenocarcinomas and oral squamous cell carcinomas.
  • Common denominators were not identified in these cases, although chronic gingivitis could have been a contributing factor in the development of the oral squamous cell carcinomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / veterinary. Macropodidae. Mammary Neoplasms, Animal / epidemiology. Mouth Neoplasms / veterinary. Stomach Neoplasms / veterinary
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / veterinary. Animals. Animals, Zoo. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / veterinary. Female. Immunohistochemistry / veterinary. Lipoma / epidemiology. Lipoma / mortality. Lipoma / pathology. Lipoma / veterinary. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679506.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Li X, Liu HG, Xie XJ, Han YD, Li M: [Clinicopathologic study of sinonasal teratocarcinosarcoma and its contrast with olfactory neuroblastoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Jul;37(7):458-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinicopathologic features, diagnosis and differential diagnosis of sinonasal teratocarcinosarcoma (SNTCS) and olfactory neuroblastoma (ONB), and to discuss the histogenesis and possible relationship between SNTCS and ONB.
  • The carcinoma component exhibited mostly adenocarcinoma and squamous cell carcinoma, whereas the sarcoma component mostly exhibited rhabdomyosarcoma, leiomyosarcoma, and fibrosarcoma.
  • In the immature embryonic tissue, rudimentary organs were formed, with fetal clear cell squamous epithelium lining present on the nasal and oral cavities surface.
  • As SNTCS may demonstrate a multiplicity of structures and pleomorphism, inadequate sampling at biopsy, therefore, may lead to errors in diagnosis.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nasal Cavity / pathology. Phosphopyruvate Hydratase. Rhabdomyosarcoma / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035117.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


58. Krawczyk M, Mykała-Cieśla J, Kołodziej-Jaskuła A: Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn; 2009 Mar;119(3):180-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acanthosis nigricans (AN) is a skin disorder characterized by focal or diffuse hyperkeratosis symmetric hyperpigmentation of the skin and oral cavity mucosa.
  • Both have been associated with gastric adenocarcinoma.
  • [MeSH-major] Acanthosis Nigricans / complications. Acanthosis Nigricans / diagnosis. Adenocarcinoma / diagnosis. Adenocarcinoma / etiology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / etiology

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514649.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 8
  •  go-up   go-down


59. Rahman B, Mamoon N, Jamal S, Zaib N, Luqman M, Mushtaq S, Anwar M: Malignant tumors of the minor salivary glands in northern Pakistan: a clinicopathological study. Hematol Oncol Stem Cell Ther; 2008 Apr-Jun;1(2):90-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant tumors of the minor salivary glands comprise a small but significant proportion of oral cancers.
  • Twenty-three of these (32.8%) arose in the palate while the remaining tumors originated at other sites in the oral cavity.
  • There were 2 cases each of polymorphous low-grade adenocarcinoma and clear cell adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063536.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


60. Sithanandam G, Anderson LM: The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther; 2008 Jul;15(7):413-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies of ERBB3 expression in primary cancers and of its mechanistic contributions in cultured cells have implicated it, with varying degrees of certainty, with causation or sustenance of cancers of the breast, ovary, prostate, certain brain cells, retina, melanocytes, colon, pancreas, stomach, oral cavity and lung.
  • Small inhibitory RNA (siRNA) to ERBB3 or AKT is showing promise as a therapeutic approach to treatment of lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Detect Prev. 2005;29(3):249-55 [15936593.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1182-95 [15790591.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4835-42 [16000581.001]
  • [Cites] Expert Opin Investig Drugs. 2005 Jun;14(6):591-606 [16004590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5 [15994225.001]
  • [Cites] Mol Pharmacol. 2005 Aug;68(2):502-10 [15908515.001]
  • [Cites] Glia. 2005 Aug 15;51(3):217-28 [15812817.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):665-84 [16035612.001]
  • [Cites] J Appl Physiol (1985). 2005 Jul;99(1):298-307 [15731393.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):575-84 [16036108.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5007-18 [16051952.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6967-75 [16061682.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):589-95 [17701904.001]
  • [Cites] Br J Cancer. 2007 Aug 20;97(4):453-7 [17667926.001]
  • [Cites] Structure. 2007 Aug;15(8):942-54 [17697999.001]
  • [Cites] EMBO J. 2007 Sep 5;26(17):3936-44 [17690690.001]
  • [Cites] Int J Oncol. 2007 Oct;31(4):851-8 [17786317.001]
  • [Cites] FEBS Lett. 2007 Sep 18;581(23):4450-4 [17765895.001]
  • [Cites] Cell Mol Life Sci. 2007 Sep;64(18):2358-77 [17530167.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Aug;66(8):740-9 [17882018.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Sep;7(6):591-604 [17896924.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1349-57 [16170026.001]
  • [Cites] BMC Genomics. 2005;6:109 [16107210.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(20):9082-91 [16199884.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22 [16203769.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9455-62 [16230409.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Nov;33(5):490-9 [16055672.001]
  • [Cites] Prostate. 2005 Dec 1;65(4):306-15 [16015604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15224-9 [16203963.001]
  • [Cites] Breast Cancer Res. 2007;9(5):111 [17983482.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Mar;134(3):337-44 [17704947.001]
  • [Cites] J Surg Res. 2008 May 1;146(1):43-8 [17631905.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1935-42 [17332320.001]
  • [Cites] Cell Growth Differ. 1996 May;7(5):551-61 [8732665.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1995 Nov;30(11):658-61 [8745489.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Sep 4;226(1):59-69 [8806592.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3663-74 [9851973.001]
  • [Cites] J Biol Chem. 1999 Jan 8;274(2):859-66 [9873025.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1629-34 [9815853.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):305-14 [9927187.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):713-21 [9927298.001]
  • [Cites] Gene. 1999 Mar 18;229(1-2):215-21 [10095121.001]
  • [Cites] EMBO J. 1999 Apr 15;18(8):2149-64 [10205169.001]
  • [Cites] FEBS Lett. 1999 Mar 26;447(2-3):227-31 [10214951.001]
  • [Cites] J Pathol. 2007 Oct;213(2):180-9 [17891747.001]
  • [Cites] Chin Med J (Engl). 2007 Sep 5;120(17):1505-10 [17908459.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):32689-98 [17823122.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(17):2602-11 [17920261.001]
  • [Cites] Trends Mol Med. 2007 Dec;13(12):527-34 [17981505.001]
  • [Cites] J Appl Physiol (1985). 2007 Dec;103(6):2077-83 [17916677.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):73-80 [17962208.001]
  • [Cites] Breast Cancer Res. 2007;9(4):R50 [17686159.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):7-11 [16843261.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):39-50 [16843264.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10917-22 [16832058.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4372s-4376s [16857813.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4409s-4415s [16857819.001]
  • [Cites] Neoplasia. 2006 Jul;8(7):613-22 [16867224.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:419-26 [16869779.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):769-75 [16896310.001]
  • [Cites] Mol Cancer Ther. 2006 Aug;5(8):2051-9 [16928826.001]
  • [Cites] Clin Breast Cancer. 2006 Aug;7(3):254-61 [16942643.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):25-33 [16872715.001]
  • [Cites] Int J Oncol. 1998 Nov;13(5):1061-7 [9772300.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):1949-57 [9788438.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 29;251(3):903-6 [9791008.001]
  • [Cites] Mol Biol Cell. 1998 Nov;9(11):3195-209 [9802906.001]
  • [Cites] Clin Cancer Res. 1995 May;1(5):545-50 [9816014.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1413-20 [9815939.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1385-90 [9823984.001]
  • [Cites] Endocrinology. 1998 Dec;139(12):4756-64 [9832411.001]
  • [Cites] Dev Biol. 1998 Dec 1;204(1):97-110 [9851845.001]
  • [Cites] Scand J Clin Lab Invest. 2006;66(7):623-30 [17101554.001]
  • [Cites] Cell Prolif. 2006 Dec;39(6):563-74 [17109639.001]
  • [Cites] Trends Cell Biol. 2006 Dec;16(12):649-56 [17085050.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11279-86 [17145873.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19063-8 [17148612.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7232-41 [17189394.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):366-76 [17200208.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1A):481-6 [10226586.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 May;20(5):914-23 [10226061.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2681-9 [10348342.001]
  • [Cites] EMBO J. 1999 Jun 15;18(12):3348-58 [10369675.001]
  • [Cites] Oncogene. 1999 Jun 10;18(23):3440-51 [10376522.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2843-6 [10383144.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2891-7 [10383151.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3503-10 [17173075.001]
  • [Cites] Int J Mol Med. 2007 Jul;20(1):3-10 [17549382.001]
  • [Cites] Nat Med. 2007 Jun;13(6):675-7 [17554333.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul;1772(7):737-47 [17553674.001]
  • [Cites] BJU Int. 2007 Aug;100(2):303-9 [17532856.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6544-8 [17638862.001]
  • [Cites] Mol Cancer Res. 2007 Jul;5(7):675-84 [17634423.001]
  • [Cites] Microsurgery. 2007;27(5):429-38 [17596863.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4326-30 [17671112.001]
  • [Cites] Genomics. 2007 Sep;90(3):344-53 [17604597.001]
  • [Cites] J Cell Sci. 2007 Aug 15;120(Pt 16):2763-73 [17652160.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1498-503 [17627612.001]
  • [Cites] J Vet Med Sci. 1998 May;60(5):549-54 [9637286.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1825-36 [9637684.001]
  • [Cites] Oncogene. 1998 May 28;16(21):2803-13 [9652748.001]
  • [Cites] Neurosci Res. 1998 Apr;30(4):351-4 [9678639.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):757-63 [9677338.001]
  • [Cites] Oncogene. 1998 Jun 25;16(25):3243-52 [9681822.001]
  • [Cites] Biochem J. 1998 Aug 15;334 ( Pt 1):189-95 [9693119.001]
  • [Cites] J Biol Chem. 1998 Aug 14;273(33):20996-1002 [9694850.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2727-32 [9703936.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):771-7 [9712416.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):6090-101 [9742126.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26954-61 [9756944.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1874-82 [17266042.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):393-401 [17426253.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1030-41 [17124505.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):517-31 [8615665.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1679-87 [8622888.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1781-8 [8622899.001]
  • [Cites] J Biol Chem. 1996 Mar 1;271(9):5251-7 [8617810.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3884-90 [8632008.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2452-67 [8665853.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5958-62 [8650201.001]
  • [Cites] J Pathol. 1996 Feb;178(2):140-5 [8683379.001]
  • [Cites] Prostate. 1996 Jun;28(6):392-405 [8650077.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2623-6 [8669836.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5485-8 [12359757.001]
  • [Cites] Apoptosis. 2002 Dec;7(6):483-91 [12370490.001]
  • [Cites] In Vivo. 2005 Sep-Oct;19(5):931-41 [16097449.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(17):7734-42 [16107719.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5597-604 [16110019.001]
  • [Cites] Prostate. 2005 Oct 1;65(2):130-40 [15880609.001]
  • [Cites] Invest New Drugs. 2005 Oct;23(5):391-409 [16133791.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7525-9 [16140912.001]
  • [Cites] Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64 [16163160.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8423-32 [16166321.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R708-18 [16168116.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):495-505 [12620236.001]
  • [Cites] Mol Biol (Mosk). 2003 Jan-Feb;37(1):97-111 [12624952.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):322-6 [12646923.001]
  • [Cites] Curr Opin Cell Biol. 2003 Apr;15(2):143-8 [12648669.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):14-30 [12648463.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):31-53 [12648464.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):54-65 [12648465.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):89-98 [12648468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15024-9 [16203964.001]
  • [Cites] Exp Oncol. 2005 Sep;27(3):225-8 [16244586.001]
  • [Cites] Nucleic Acids Res. 2005;33(18):6024-33 [16254079.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):209-14 [16003751.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] Biochemistry. 2005 Dec 6;44(48):15842-57 [16313187.001]
  • [Cites] Biochem J. 2005 Dec 15;392(Pt 3):417-23 [16122376.001]
  • [Cites] J Neurosci. 1996 Oct 1;16(19):6107-18 [8815893.001]
  • [Cites] Pathol Res Pract. 1995 Oct;191(10):973-81 [8838364.001]
  • [Cites] J Pathol. 1996 Aug;179(4):381-5 [8869284.001]
  • [Cites] Cancer Surv. 1996;27:339-49 [8909809.001]
  • [Cites] J Neurosci. 1997 Mar 1;17(5):1642-59 [9030624.001]
  • [Cites] Br J Urol. 1997 Feb;79(2):212-6 [9052472.001]
  • [Cites] Cancer J Sci Am. 1997 Jan-Feb;3(1):21-30 [9072304.001]
  • [Cites] Biochem J. 1997 Mar 15;322 ( Pt 3):757-63 [9148746.001]
  • [Cites] Biochem J. 1997 Apr 1;323 ( Pt 1):113-8 [9173868.001]
  • [Cites] Mod Pathol. 1997 Feb;10(2):142-8 [9127320.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12052-6 [9115272.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1319-30 [9137492.001]
  • [Cites] Oncogene. 1997 Jul 24;15(4):473-81 [9242384.001]
  • [Cites] EMBO J. 1997 Sep 15;16(18):5608-17 [9312020.001]
  • [Cites] Nature. 1997 Oct 16;389(6652):725-30 [9338783.001]
  • [Cites] J Cell Physiol. 1997 Nov;173(2):187-95 [9365520.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5195-201 [9389501.001]
  • [Cites] Oncogene. 1997 Nov 27;15(22):2705-16 [9400997.001]
  • [Cites] Exp Neurol. 1997 Dec;148(2):604-15 [9417836.001]
  • [Cites] Curr Biol. 1998 Jan 1;8(1):R15-8 [9427620.001]
  • [Cites] Development. 1997 Dec;124(24):4999-5011 [9362461.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):335-46 [9440030.001]
  • [Cites] Oncology. 1998 Mar-Apr;55(2):161-7 [9499191.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4539-46 [9494565.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7717-24 [9516479.001]
  • [Cites] Oncogene. 1998 Mar 12;16(10):1249-58 [9546426.001]
  • [Cites] Nature. 1998 May 7;393(6680):83-5 [9590694.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13819-27 [9593726.001]
  • [Cites] Mol Cancer Ther. 2004 Apr;3(4):465-72 [15078990.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):317-28 [15093539.001]
  • [Cites] Chest. 2004 May;125(5 Suppl):141S-4S [15136468.001]
  • [Cites] J Pathol. 2004 Jun;203(2):688-95 [15141384.001]
  • [Cites] Ai Zheng. 2004 May;23(5):568-72 [15142456.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3395-405 [15150091.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Oncogene. 2004 May 27;23(25):4454-65 [15064750.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Curr Pharm Des. 2004;10(15):1739-44 [15180536.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):26126-33 [15073182.001]
  • [Cites] FEBS Lett. 2004 Jul 2;569(1-3):332-6 [15225657.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):27306-16 [16825199.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4317-23 [16896008.001]
  • [Cites] Syst Biol (Stevenage). 2006 Jan;153(1):22-33 [16983832.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1309-15 [17001163.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):998-1004 [17047648.001]
  • [Cites] BMC Evol Biol. 2006;6:79 [17026767.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55 [17062680.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2986-7 [16998794.001]
  • [Cites] Pediatr Pulmonol. 2006 Dec;41(12):1205-12 [17063476.001]
  • [Cites] Adv Cancer Res. 2000;77:25-79 [10549355.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):6050-62 [10557094.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Dec;21(6):701-9 [10572067.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2358-68 [10582594.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):767-74; discussion 774-5 [10615931.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4164-74 [10632356.001]
  • [Cites] J Histochem Cytochem. 2000 Jan;48(1):63-80 [10653587.001]
  • [Cites] Dev Neurosci. 2000;22(1-2):16-24 [10657694.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):1479-86 [17110380.001]
  • [Cites] J Invest Dermatol. 2007 Feb;127(2):394-9 [16946712.001]
  • [Cites] Nature. 2007 Jan 25;445(7126):437-41 [17206155.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1293-303 [17163417.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1645-52 [17308105.001]
  • [Cites] J Biol Chem. 1996 Jun 7;271(23):13491-6 [8662847.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):229-33 [8688326.001]
  • [Cites] Cancer Lett. 1999 Jul 19;142(1):55-63 [10424781.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2861-78 [10473632.001]
  • [Cites] Exp Neurol. 1999 Oct;159(2):494-503 [10506520.001]
  • [Cites] World J Surg. 1999 Oct;23(10):1010-8 [10512940.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):47050-6 [15345710.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):517-27 [15542435.001]
  • [Cites] Thorax. 2004 Dec;59(12):1032-40 [15563701.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):97-107 [15571795.001]
  • [Cites] Cancer Invest. 2004;22(5):706-12 [15581051.001]
  • [Cites] Cancer Invest. 2004;22(6):858-65 [15641483.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1321-6 [15520002.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):226-35 [15665299.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):140-6 [15583694.001]
  • [Cites] Mol Hum Reprod. 2005 Feb;11(2):133-40 [15591450.001]
  • [Cites] Melanoma Res. 2005 Feb;15(1):21-8 [15714117.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):846-53 [15720812.001]
  • [Cites] J Neurosci Res. 2005 Mar 1;79(5):584-97 [15682390.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8238-47 [15611073.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1778-82 [15753374.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1704-12 [15755991.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93 [15731348.001]
  • [Cites] Oncogene. 2005 Mar 10;24(11):1847-59 [15688028.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2163-8 [15788662.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1177-85 [15809707.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1670-5 [15751020.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):519-27 [15704104.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4253-60 [15899817.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2597-605 [11135221.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5471-6 [11114724.001]
  • [Cites] Eur Respir J. 2000 Nov;16(5):991-6 [11153605.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6102-14 [11156523.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 11):76-83; discussion 92-100 [11236032.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] J Cell Physiol. 2001 May;187(2):209-17 [11268000.001]
  • [Cites] Nat Neurosci. 2001 Apr;4(4):374-81 [11276227.001]
  • [Cites] J Comp Neurol. 2001 Apr 23;433(1):86-100 [11283951.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14407-13 [11278550.001]
  • [Cites] Chin Med Sci J. 1997 Jun;12(2):67-70 [11324501.001]
  • [Cites] Mol Cell Endocrinol. 2001 Apr 25;175(1-2):185-91 [11325528.001]
  • [Cites] J Cell Sci. 2002 Nov 15;115(Pt 22):4251-62 [12376557.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3438-44 [12429632.001]
  • [Cites] Mol Biol Cell. 2002 Nov;13(11):4029-44 [12429844.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14843-8 [12411582.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6510-8 [12438245.001]
  • [Cites] J Biochem Mol Toxicol. 2002;16(5):209-19 [12439862.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3933-42 [12473609.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8732-40 [12483526.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1294-301 [12618754.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2866-71 [11867753.001]
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):8961-9 [11779863.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1065-71 [12008194.001]
  • [Cites] Virchows Arch. 2002 May;440(5):476-84 [12021921.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3132-7 [12036925.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3151-8 [12036928.001]
  • [Cites] J Cell Biol. 2002 Jun 10;157(6):929-39 [12045181.001]
  • [Cites] Dev Dyn. 2002 Jul;224(3):356-60 [12112465.001]
  • [Cites] Exp Cell Res. 2003 Apr 1;284(2):291-302 [12651161.001]
  • [Cites] Nucleic Acids Res. 2003 Apr 15;31(8):2168-77 [12682367.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1274-83 [12684395.001]
  • [Cites] Mol Cell Endocrinol. 2003 Mar 28;201(1-2):39-46 [12706292.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1775-81 [12721254.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Jun;284(6):G996-1005 [12571082.001]
  • [Cites] Oncogene. 2003 May 22;22(21):3205-12 [12761490.001]
  • [Cites] Br J Cancer. 2005 Dec 12;93(12):1334-40 [16288303.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11478-85 [16357156.001]
  • [Cites] Urology. 2005 Dec;66(6):1197-202 [16360440.001]
  • [Cites] Nature. 2006 Jan 12;439(7073):168-74 [16273093.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):831-42 [16428439.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):184-8 [16434982.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1418-26 [16452197.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 10):S3-8 [16459173.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89 [16467077.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jan;95(1):17-27 [16267617.001]
  • [Cites] Acta Med Okayama. 2006 Feb;60(1):25-34 [16508686.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1647-53 [16533793.001]
  • [Cites] Cell Signal. 2006 Jul;18(7):923-33 [16460914.001]
  • [Cites] BMC Cancer. 2006;6:46 [16507107.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1054-67 [16401639.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 9;344(3):859-68 [16631606.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2730-7 [16675564.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7789-94 [16682621.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3078-84 [16707605.001]
  • [Cites] Mol Syst Biol. 2005;1:2005.0008 [16729043.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1703-9 [16685269.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):727-34 [16557579.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1137-49 [16777603.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4103-11 [16818711.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L175-80 [16489114.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19310-9 [16690615.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Curr Opin Pharmacol. 2006 Aug;6(4):323-31 [16765644.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):449-54 [14735192.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):646-53 [14737100.001]
  • [Cites] Lung Cancer. 2004 Feb;43(2):135-43 [14739033.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):446-51 [14744754.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):923-8 [14732693.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):929-34 [14732694.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4479-89 [14602723.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1197-205 [14647450.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):332-7 [15264245.001]
  • [Cites] Biochim Biophys Acta. 2004 Aug 4;1673(3):194-200 [15279891.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41 [15292385.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7748-57 [15314180.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7078-85 [15466203.001]
  • [Cites] Int J Oncol. 2004 Nov;25(5):1489-94 [15492843.001]
  • [Cites] Adv Protein Chem. 2004;68:1-27 [15500857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9193-7 [2687875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):4905-9 [2164210.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7792-6 [1715580.001]
  • [Cites] Br J Cancer. 1992 Dec;66(6):1116-21 [1333787.001]
  • [Cites] J Pathol. 1992 Nov;168(3):269-73 [1361525.001]
  • [Cites] J Pathol. 1992 Nov;168(3):275-80 [1361526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1746-50 [8383326.001]
  • [Cites] Biochem Biophys Res Commun. 1993 May 14;192(3):1189-97 [7685162.001]
  • [Cites] Int J Cancer. 1993 Jul 30;54(6):935-40 [8335401.001]
  • [Cites] Oncogene. 1993 Dec;8(12):3393-401 [8247542.001]
  • [Cites] Gastroenterology. 1999 Nov;117(5):1119-27 [10535875.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):683-90 [10682683.001]
  • [Cites] Tumour Biol. 2000 Mar-Apr;21(2):105-15 [10686540.001]
  • [Cites] Regul Pept. 2000 Feb 8;87(1-3):73-82 [10710290.001]
  • [Cites] J Cell Biochem. 1999 Jun 15;73(4):522-32 [10733345.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Apr;22(4):432-40 [10745024.001]
  • [Cites] Oncogene. 2000 Mar 23;19(13):1647-56 [10763821.001]
  • [Cites] Cell Growth Differ. 2000 Mar;11(3):173-83 [10768865.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):492-500 [8264617.001]
  • [Cites] J Pathol. 1993 Jul;170(3):271-8 [8133400.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14661-5 [7514177.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3550-8 [7515147.001]
  • [Cites] EMBO J. 1994 Jun 15;13(12):2831-41 [8026468.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1140-5 [7913137.001]
  • [Cites] FEBS Lett. 1994 Jul 25;349(1):139-43 [8045292.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6 [8058768.001]
  • [Cites] J Biol Chem. 1994 Oct 7;269(40):24747-55 [7929151.001]
  • [Cites] Histopathology. 1994 Sep;25(3):247-52 [7821892.001]
  • [Cites] J Neurosci. 1995 Feb;15(2):1329-40 [7869101.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4784-91 [7876251.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7111-6 [7535767.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):758-62 [7710941.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Apr;80(2):100-2 [7736422.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1813-21 [7538656.001]
  • [Cites] J Neurooncol. 1994;22(3):201-7 [7760096.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):202-6 [7622309.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):401-5 [7626487.001]
  • [Cites] Cancer Lett. 1995 Aug 16;95(1-2):79-83 [7656248.001]
  • [Cites] J Biol Chem. 1995 Sep 22;270(38):22608-13 [7673253.001]
  • [Cites] EMBO J. 1995 Sep 1;14(17):4267-75 [7556068.001]
  • [Cites] Mol Cell Biol. 1995 Dec;15(12):6496-505 [8524214.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):31119-23 [8537373.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1457-65 [8640840.001]
  • [Cites] Cell Growth Differ. 1995 Dec;6(12):1567-77 [9019162.001]
  • [Cites] J Biol Chem. 1996 Mar 15;271(11):6071-6 [8626392.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):471-4 [8615656.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):91-5 [10769639.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Apr;126(4):205-11 [10782893.001]
  • [Cites] J Biochem. 2000 May;127(5):925-30 [10788804.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):617-25 [10797281.001]
  • [Cites] J Cell Physiol. 2000 Jun;183(3):301-13 [10797304.001]
  • [Cites] J Cell Physiol. 2000 Jun;183(3):321-9 [10797306.001]
  • [Cites] J Mol Evol. 2000 May;50(5):397-412 [10824084.001]
  • [Cites] Biochemistry. 2000 Jul 25;39(29):8503-11 [10913256.001]
  • [Cites] Int J Cancer. 2000 Sep 15;87(6):763-70 [10956383.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):629-41 [10995872.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):30934-42 [10908564.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 2;277(3):757-63 [11062025.001]
  • [Cites] Breast Cancer Res Treat. 2000 Sep;63(1):61-9 [11079160.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4217-25 [11106235.001]
  • [Cites] J Allergy Clin Immunol. 2000 Dec;106(6):1124-31 [11112896.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5568-73 [11114736.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):43-52 [11326315.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1424-31 [11355958.001]
  • [Cites] Biol Reprod. 2001 Jun;64(6):1835-44 [11369616.001]
  • [Cites] Cell Signal. 2001 May;13(5):321-30 [11369513.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4467-73 [11389077.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22685-98 [11297548.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):268-79 [11425269.001]
  • [Cites] Cytometry. 2001 Aug 1;44(4):338-48 [11500850.001]
  • [Cites] Oncogene. 2001 Aug 23;20(37):5199-209 [11526509.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7184-8 [11585753.001]
  • [Cites] J Pathol. 2001 Oct;195(3):343-8 [11673832.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42153-61 [11546794.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 23;289(1):240-4 [11708806.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):44266-74 [11555649.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1868-76 [11789762.001]
  • [Cites] Oncogene. 2002 Jan 3;21(1):78-86 [11791178.001]
  • [Cites] Exp Brain Res. 2002 Jan;142(1):81-90 [11797086.001]
  • [Cites] J Allergy Clin Immunol. 2002 Jan;109(1):75-81 [11799369.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4704-12 [11741943.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1159-66 [11850835.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jan;71(1):47-57 [11859873.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4132-41 [12124352.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5609-18 [12165860.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1330-3 [12154198.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Sep;27(3):306-13 [12204892.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):127-37 [12204533.001]
  • [Cites] J Recept Signal Transduct Res. 1999 Nov;19(6):885-908 [10533979.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):697-702 [12209129.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20971-8 [12600989.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3598-607 [12789268.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1711-6 [12663324.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23630-8 [12714585.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1455-60 [12820409.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3764-74 [12839972.001]
  • [Cites] Genome Res. 2003 Jul;13(7):1744-53 [12840049.001]
  • [Cites] J Pathol. 2003 Jul;200(3):290-7 [12845624.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):758-65 [12866037.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8 [12853564.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9226-31 [12874383.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35702-9 [12824184.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):736-41 [14514775.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):541-52 [14527402.001]
  • [Cites] Carcinogenesis. 2003 Oct;24(10):1581-92 [12896906.001]
  • [Cites] Expert Rev Mol Med. 2003 May;5(14):1-11 [14585167.001]
  • [Cites] Med Oral. 2003 Nov-Dec;8(5):374-81 [14595263.001]
  • [Cites] J Invest Dermatol. 2003 Oct;121(4):802-12 [14632199.001]
  • [Cites] Glia. 2004 Jan 15;45(2):197-207 [14730713.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):289-93 [14735165.001]
  • (PMID = 18404164.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CO / N01 CO012400; United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z01 BC005399-24; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neuregulins; 0 / RNA, Small Interfering; EC 2.7.10.1 / Receptor, ErbB-3
  • [Number-of-references] 438
  • [Other-IDs] NLM/ NIHMS107476; NLM/ PMC2761714
  •  go-up   go-down


61. Narayana A, Cohen GN, Zaider M, Chan K, Lee N, Wong RJ, Boyle J, Shaha A, Kraus D, Shah J, Zelefsky MJ: High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results. Brachytherapy; 2007 Apr-Jun;6(2):157-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment sites were oral cavity/oropharynx (11/30), neck (10/30), face/nasal cavity (6/30), and parotid bed (3/30).
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Follow-Up Studies. Humans. Male. Melanoma / radiotherapy. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Retrospective Studies. Sarcoma / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden / radiation effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434110.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Angiero F, Stefani M: Hyalinizing clear cell carcinoma arising on the anterior palatoglossal arch. Anticancer Res; 2007 Nov-Dec;27(6C):4271-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyalinizing clear cell carcinoma (HCCC) is very rare in the oral cavity, arising more frequently in the minor salivary glands.
  • This report focuses on the heterogeneous group of clear cell neoplasms with the intent of pointing out some aspects that may contribute to forming a diagnosis of HCCC, and which, above all enable us to distinguish this neoplasm from other very similar forms occurring in the oral cavity.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Mouth Neoplasms / pathology. Palatal Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Hyalin. Immunohistochemistry. Middle Aged. Palate, Hard / pathology. Palate, Hard / surgery. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18214031.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


63. De Ruyck K, de Gelder V, Van Eijkeren M, Boterberg T, De Neve W, Vral A, Thierens H: Chromosomal radiosensitivity in head and neck cancer patients: evidence for genetic predisposition? Br J Cancer; 2008 May 20;98(10):1723-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean number of radiation-induced chromatid breaks and the proportion of radiosensitive individuals were highest for oral cavity cancer patients (1.26 breaks per cell, 38%) and pharynx cancer patients (1.27 breaks per cell, 35%).
  • In conclusion, enhanced chromosomal radiosensitivity is a marker of genetic predisposition to head and neck cancer, and the genetic contribution is highest for oral cavity and pharynx cancer patients and for early onset and non- and light smoking patients.
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Age Factors. Aged. Carcinoma, Squamous Cell / genetics. Chromatids / radiation effects. DNA Damage / radiation effects. DNA Repair / radiation effects. DNA, Neoplasm. Female. Genetic Markers. Genetic Predisposition to Disease. Humans. Laryngeal Neoplasms / genetics. Logistic Models. Male. Middle Aged. Mouth Neoplasms / genetics. Odds Ratio. Pharyngeal Neoplasms / genetics. Risk Factors

  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Biol. 2002 May;78(5):341-6 [12020425.001]
  • [Cites] Int J Radiat Biol. 2002 Apr;78(4):249-57 [12020436.001]
  • [Cites] Int J Radiat Biol. 2002 Sep;78(9):863-6 [12428927.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1379-85 [12454765.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):345-52 [15093280.001]
  • [Cites] Head Neck. 1989 Jul-Aug;11(4):337-42 [2473966.001]
  • [Cites] JAMA. 1989 Dec 15;262(23):3313-5 [2479781.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):103-6 [7682127.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):329-33 [7688625.001]
  • [Cites] Lancet. 1994 Nov 19;344(8934):1444 [7968110.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):157-60 [7840922.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 17;88(8):530-5 [8606381.001]
  • [Cites] Br J Cancer. 1996 Jul;74(1):1-5 [8679441.001]
  • [Cites] BMJ. 1996 Sep 21;313(7059):716-21 [8819440.001]
  • [Cites] Int J Cancer. 1997 Sep 26;73(1):20-4 [9334804.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):614-20 [9484819.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1773-8 [9676854.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1393-9 [9747870.001]
  • [Cites] Int J Radiat Biol. 1999 Jan;75(1):1-10 [9972785.001]
  • [Cites] Am J Hum Genet. 1999 Sep;65(3):784-94 [10441587.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):726-33 [15599850.001]
  • [Cites] J Radiat Res. 2004 Dec;45(4):535-41 [15635263.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):347-53 [15643523.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):349-57 [15665313.001]
  • [Cites] J Radiat Res. 2005 Mar;46(1):111-6 [15802866.001]
  • [Cites] Int J Radiat Biol. 2005 May;81(5):373-8 [16076752.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Jun;24(2):217-22 [16110754.001]
  • [Cites] Mutagenesis. 2005 Sep;20(5):381-5 [16105906.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9566-73 [16230422.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11292-6 [16357135.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1194-203 [16538220.001]
  • [Cites] Mutagenesis. 2006 Sep;21(5):313-20 [16928695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1245-52 [17145539.001]
  • [Cites] Radiother Oncol. 2006 Dec;81(3):257-63 [17113667.001]
  • [Cites] Int J Radiat Biol. 2007 Jan;83(1):1-12 [17357435.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2735-40 [17724733.001]
  • [Cites] Int J Cancer. 1995 Dec 11;63(6):769-73 [8847131.001]
  • [Cites] Int J Radiat Biol. 2000 May;76(5):607-15 [10866282.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):533-7 [11173151.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):776-82 [11259091.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):892-6 [11286467.001]
  • [Cites] Br J Cancer. 2001 Oct 19;85(8):1157-61 [11710829.001]
  • [Cites] Acta Oncol. 2001;40(6):702-11 [11765064.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):310-7 [11981277.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):563-8 [12209748.001]
  • (PMID = 18414410.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC2391130
  •  go-up   go-down


64. Sells DM, Brix AE, Nyska A, Jokinen MP, Orzech DP, Walker NJ: Respiratory tract lesions in noninhalation studies. Toxicol Pathol; 2007 Jan;35(1):170-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nasal cavity was vulnerable to damage when chemicals were administered by noninhalation routes.
  • Changes included respiratory epithelial hyperplasia, degeneration and necrosis of olfactory epithelium, olfactory epithelial metaplasia, adenoma, adenocarcinoma, squamous cell carcinoma, and neuroblastoma.
  • [MeSH-minor] Administration, Oral. Injections. Lung / drug effects. Nasal Cavity / drug effects. Nasal Cavity / pathology. Nasal Mucosa / drug effects. Nasal Mucosa / pathology. Toxicity Tests / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gan. 1979 Feb;70(1):29-36 [446975.001]
  • [Cites] Toxicol Pathol. 2005;33(3):371-7 [15805076.001]
  • [Cites] Anticancer Res. 1981;1(5):279-86 [7345971.001]
  • [Cites] Cancer Res. 1982 Oct;42(10):4236-40 [7105017.001]
  • [Cites] Environ Health Perspect. 1990 Apr;85:177-86 [2200661.001]
  • [Cites] Environ Health Perspect. 1990 Apr;85:275-89 [2200667.001]
  • [Cites] Arch Toxicol. 1991;65(1):1-9 [2043044.001]
  • [Cites] Toxicol Pathol. 1991;19(4 Pt 1):321-36 [1813979.001]
  • [Cites] J Toxicol Environ Health A. 2002 Apr 12;65(7):523-37 [11939710.001]
  • [Cites] Toxicol Pathol. 2002 Mar-Apr;30(2):178-87 [11950161.001]
  • [Cites] Arch Toxicol. 2003 Apr;77(4):233-42 [12698239.001]
  • [Cites] Toxicol Pathol. 2004 May-Jun;32(3):333-7 [15204975.001]
  • [Cites] Toxicol Pathol. 1991;19(4 Pt 1):358-72 [1813982.001]
  • [Cites] Drug Metab Dispos. 1992 Sep-Oct;20(5):643-52 [1358567.001]
  • [Cites] Drug Metab Rev. 1993;25(1-2):173-205 [8449146.001]
  • [Cites] J Histochem Cytochem. 1993 Jun;41(6):877-85 [8315279.001]
  • [Cites] Biochem Pharmacol. 1995 May 17;49(10):1387-94 [7763281.001]
  • [Cites] Toxicol Pathol. 1996 Sep-Oct;24(5):564-72 [8923677.001]
  • [Cites] Cancer Res. 1980 Feb;40(2):298-302 [7356512.001]
  • (PMID = 17325986.001).
  • [ISSN] 0192-6233
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Xenobiotics
  • [Number-of-references] 24
  • [Other-IDs] NLM/ NIHMS33525; NLM/ PMC3433271
  •  go-up   go-down


65. Haro A, Yano T, Yoshida T, Ito K, Morodomi Y, Shoji F, Nakashima T, Maehara Y: Results of a surgical resection of pulmonary metastasis from malignant head and neck tumor. Interact Cardiovasc Thorac Surg; 2010 May;10(5):700-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both age (older than 60 years) (P=0.0189) and pulmonary metastases from squamous cell carcinomas in either oral cavity or pharyngeal region (P=0.0002) were identified to be adverse prognostic factors.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pneumonectomy / methods. Pneumonectomy / mortality. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
  • (PMID = 20123888.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Chen HL, Chang WH, Shih SC, Pang KK, Bair MJ: Trismus and trigeminal neuralgia in one patient with colon cancer. J Natl Med Assoc; 2008 Jun;100(6):740-2
MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 64-year-old man got trismus and trigeminal neuralgia under the diagnosis of colon cancer with mandibular metastasis after emergency appendectomy and elective hemicolectomy.
  • He died six months after diagnosis.
  • Metastatic tumors to the oral cavity are relatively uncommon.
  • They are found most commonly in the mandible, and 70% of cases are adenocarcinoma-most commonly from breast and lung, followed by adrenals, kidneys, prostate, thyroid and colon.
  • Tissue proof is needed to confirm the diagnosis.
  • However, the prognosis is grim, with the mean survival after diagnosis being only about 6-7 months.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Mandibular Neoplasms / secondary. Trigeminal Neuralgia / etiology. Trismus / etiology

  • Genetic Alliance. consumer health - Trigeminal neuralgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595580.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Singhi AD, Montgomery EA: Colorectal granular cell tumor: a clinicopathologic study of 26 cases. Am J Surg Pathol; 2010 Aug;34(8):1186-92
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granular cell tumor (GCT) is commonly located in the subcutaneous tissue and oral cavity, and uncommon in the gastrointestinal tract, in which the majority arises in the esophagus with over-representation in African Americans (AA).
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661017.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


68. Bhurgri Y, Nazir K, Shaheen Y, Usman A, Faridi N, Bhurgri H, Malik J, Bashir I, Bhurgri A, Hasan SH, Kayani N, Zaidi SH: Patho-epidemiology of cancer corpus uteri in Karachi South '1995-1997'. Asian Pac J Cancer Prev; 2007 Oct-Dec;8(4):489-94
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Cancer uterine corpus (1995-97) was the sixth most common malignancy, following breast, oral cavity, ovary, esophagus and cervix.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Incidence. Middle Aged. Pakistan / epidemiology. Risk Factors. Sarcoma / epidemiology. Sarcoma / pathology. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260717.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


69. Antunes AA, Antunes AP: Gnathic bone metastasis: a retrospective study of 10 cases. Braz J Otorhinolaryngol; 2008 Jul-Aug;74(4):561-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral cavity metastases are extremely rare, and comprise 1% of all mouth malignant neoplasms.
  • The thyroid and prostate glands were the most prevalent primary tumor sites for metastases (03 cases each); the adenocarcinoma histological type had the highest metastatic rate (50%).
  • The thyroid and prostate seem to be the most frequent sites of distance metastasis of the jaws; the adenocarcinoma is the most frequent histological type causing such metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852982.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


70. Ahmad Z, Azad NS, Yaqoob N, Husain A, Ahsan A, Khan AN, Ahmed R, Kayani N, Pervez S, Hassan SH: Frequency of primary solid malignant neoplasms in both sexes, as seen in our practice. J Ayub Med Coll Abbottabad; 2007 Jan-Mar;19(1):53-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Squamous cell carcinoma of oral cavity was the commonest malignant neoplasm in males followed by diffuse Large B cell, Non-Hodgkin's lymphoma and Prostatic adenocarcinoma.
  • In females, infiltrating Ductal carcinoma of the breast was overwhelmingly the commonest malignant neoplasm followed by Squamous cell carcinoma of the oral cavity and esophagus.
  • Carcinoma of oral cavity is very common in our population in both sexes.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Non-Hodgkin / epidemiology. Neoplasms, Squamous Cell / epidemiology. Prostatic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867482.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


71. Nakaichi M, Yunuki T, Okuda M, Une S, Taura Y: Activity of matrix metalloproteinase-2 (MMP-2) in canine oronasal tumors. Res Vet Sci; 2007 Apr;82(2):271-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue samples from melanoma and squamous cell carcinoma possessed higher MMP-2 activity, as shown in gelatin zymography, in comparison with acanthomatous epulis and nasal adenocarcinoma.
  • However, the MMP-2/TIMP-2 ratio showed a significantly higher level of the genes in the malignant oral melanoma and squamous cell carcinoma.
  • These results indicate that the MMP-2/TIMP-2 ratio may be of value in evaluating the prognosis in canine oronasal cavity tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Dog Diseases / enzymology. Matrix Metalloproteinase 2 / metabolism. Melanoma / veterinary. Mouth Neoplasms / veterinary. Nose Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011604.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


72. Lukes P, Astl J, Pavlík E, Potuzníková B, Sterzl I, Betka J: Helicobacter pylori in tonsillar and adenoid tissue and its possible role in oropharyngeal carcinogenesis. Folia Biol (Praha); 2008;54(2):33-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It plays a major role in the pathogenesis of chronic gastritis, duodenal and gastric ulcers, adenocarcinoma and gastric lymphoma.
  • Recently, the oral cavity was proposed as an extragastric reservoir of HP infection.
  • In this review, recent findings about oral HP are considered.
  • Possibilities of diagnostics of HP in oral specimens are discussed.

  • MedlinePlus Health Information. consumer health - Adenoids.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498719.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 66
  •  go-up   go-down


73. Sasaki H, Ohara N, Minamikawa T, Umeda M, Komori T, Kojima N, Takemura N, Morita H, Sugihara R, Enoki E, Itoh T: Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report). Kobe J Med Sci; 2008;54(3):E174-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The metastasis of malignant tumors to the oral cavity remains a rare clinical entity.
  • Most metastatic tumors have the propensity for involving the mandible rather than the oral soft tissues.
  • There is little information regarding metastatic ovarian cancer to the oral cavity.
  • A biopsy taken from the gingiva showed mucinous adenocarcinoma, indicating the gingival metastasis of undiscovered primary cancer.
  • Based on the imaging studies, the diagnosis of the gingival metastasis of an ovarian cancer was suspected.
  • The histology of surgical specimen confirmed the gingival metastasis of ovarian mucinous adenocarcinoma.
  • This case emphasizes that although rare, metastatic ovarian cancer to the gingiva should be included in the differential diagnosis of tumors in the oral cavity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246966.001).
  • [ISSN] 1883-0498
  • [Journal-full-title] The Kobe journal of medical sciences
  • [ISO-abbreviation] Kobe J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


74. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.
  • Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT.
  • Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Huang H, Xie BF, Zhu XF, Feng GK, Zhou JM, Wang Y, Wu HQ, Huang ZS, Gu LQ, Liu ZC: [Antitumor effect and mechanism of shikonin derivative SYUNZ-7]. Ai Zheng; 2005 Dec;24(12):1453-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In vitro antiproliferation effects of SYUNZ-7 on human lung adenocarcinoma cell line GLC-82, human nasopharyngeal cancer cell line CNE2, human oral cavity cancer cell line KB, human gastric cancer cell line MGC-803 and human hepatocellular cancer cell line HepG2 were tested by MTT assay.

  • Hazardous Substances Data Bank. Shikonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351791.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Naphthoquinones; 0 / SYUNZ-7; 3IK6592UBW / shikonin
  •  go-up   go-down


76. Hadler-Olsen E, Wetting HL, Rikardsen O, Steigen SE, Kanapathippillai P, Grénman R, Winberg JO, Svineng G, Uhlin-Hansen L: Stromal impact on tumor growth and lymphangiogenesis in human carcinoma xenografts. Virchows Arch; 2010 Dec;457(6):677-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell carcinomas (SCCs) arising in the oral cavity are associated with poor survival, mainly due to metastatic disease.
  • Two oral and two skin SCC cell lines were used, as well as an endometrial adenocarcinoma cell line.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2004 Nov;445(5):456-64 [15375658.001]
  • [Cites] Histopathology. 2005 Aug;47(2):186-94 [16045780.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1232-42 [15803182.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7344-53 [16243806.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8364-71 [16322297.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4184-90 [16141354.001]
  • [Cites] Lymphology. 2005 Sep;38(3):107-10 [16353487.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2650-7 [16510584.001]
  • [Cites] J Pathol. 2006 May;209(1):67-77 [16482496.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Cancer Metastasis Rev. 2006 Jun;25(2):221-32 [16770534.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1779-87 [16931911.001]
  • [Cites] Immunol Rev. 2007 Jun;217:155-67 [17498058.001]
  • [Cites] Trends Immunol. 2007 Aug;28(8):340-5 [17627888.001]
  • [Cites] Adv Immunol. 2007;95:167-255 [17869614.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):554-6 [18538738.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] Mutat Res. 2008 Jul-Aug;659(1-2):15-30 [18485806.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] J Oral Pathol Med. 2008 Nov;37(10):616-25 [19012622.001]
  • [Cites] PLoS One. 2008;3(11):e3812 [19043576.001]
  • [Cites] Circulation. 2009 Jan 20;119(2):281-9 [19118255.001]
  • [Cites] Ann Surg Oncol. 2009 Feb;16(2):233-9 [18825461.001]
  • [Cites] Am J Otolaryngol. 2009 Mar-Apr;30(2):121-33 [19239954.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):177-83 [19259624.001]
  • [Cites] Mol Oncol. 2008 Jun;2(1):41-53 [19383328.001]
  • [Cites] J Cell Biochem. 2009 Aug 15;107(6):1053-62 [19479945.001]
  • [Cites] J Histochem Cytochem. 2010 Jan;58(1):29-39 [19755718.001]
  • [Cites] Eur J Cancer. 2011 Jan;47(2):305-15 [20932741.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):32127-36 [10542248.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2821-8 [10914730.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1223-31 [11250889.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4762-73 [11532940.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):293-8 [11801572.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1315-20 [11888898.001]
  • [Cites] Head Neck. 2002 Feb;24(2):165-80 [11891947.001]
  • [Cites] J Cell Physiol. 2002 Sep;192(3):259-67 [12124771.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1317-23 [12429983.001]
  • [Cites] Blood. 2003 Jan 1;101(1):168-72 [12393704.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] APMIS. 2003 Nov;111(11):1011-8 [14629267.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jan;33(1):2-7 [14690652.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):74-80 [14634646.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 May;118(5):542-7 [1571132.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3566-70 [7724599.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):290-98 [8617204.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Science. 1997 May 30;276(5317):1423-5 [9162011.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3898-911 [9233800.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53 [9435229.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):385-94 [10027397.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):789-801 [10037799.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(3):279-84 [10352881.001]
  • (PMID = 20890764.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Serum Amyloid P-Component; 0 / Vascular Endothelial Growth Factor C
  • [Other-IDs] NLM/ PMC2995317
  •  go-up   go-down


77. Deng HB, Wang ZQ, Xu ZY: [Inhibitory effects of Feiyanning Decoction on proliferation, migration and tube formation of human umbilical vein endothelial cells in vitro]. Zhong Xi Yi Jie He Xue Bao; 2009 Mar;7(3):255-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum containing Feiyanning was prepared in SD rats by oral gavage of the Feiyanning Decoction for three days.
  • The inhibitory effects of different contents of serum containing Feiyanning on the proliferation of HUVECs, human lung adenocarcinoma cell A549, and HUVECs cultured with A549-conditioned media were observed by sulforhodamine B (SRB) method; the effects on migration of HUVECs were inspected by using Boyden Chamber Transwell method, and the effects on tube formation of HUVECs were evaluated by cavity forming experiment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284956.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


78. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K: Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res; 2007 Jul;168(1):1-64
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant radiation-associated increases in risk were seen for most sites, including oral cavity, esophagus, stomach, colon, liver, lung, non-melanoma skin, breast, ovary, bladder, nervous system and thyroid.
  • Elevated risks were seen for all of the five broadly classified histological groups considered, including squamous cell carcinoma, adenocarcinoma, other epithelial cancers, sarcomas and other non-epithelial cancers.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722996.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31021; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


79. Ren JS, Freedman ND, Kamangar F, Dawsey SM, Hollenbeck AR, Schatzkin A, Abnet CC: Tea, coffee, carbonated soft drinks and upper gastrointestinal tract cancer risk in a large United States prospective cohort study. Eur J Cancer; 2010 Jul;46(10):1873-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During 2,584,953 person-years of follow-up on 481,563 subjects, 392 oral cavity, 178 pharynx, 307 larynx, 231 gastric cardia, 224 gastric non-cardia cancer, 123 Oesophageal Squamous Cell Carcinoma (ESCC) and 305 Oesophageal Adenocarcinoma (EADC) cases were accrued.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ltd.
  • [Cites] J Natl Cancer Inst. 1994 Jun 1;86(11):855-8 [8182766.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1369-75 [8339227.001]
  • [Cites] Epidemiology. 1994 Nov;5(6):583-90 [7841239.001]
  • [Cites] Cancer Causes Control. 1995 Jan;6(1):57-67 [7718736.001]
  • [Cites] Cancer Causes Control. 1998 Mar;9(2):209-16 [9578298.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):614-20 [10408875.001]
  • [Cites] J Agric Food Chem. 2004 Dec 29;52(26):8268-71 [15612828.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Apr-Jun;6(2):202-7 [16101334.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):72-5 [16391374.001]
  • [Cites] Cad Saude Publica. 2006 May;22(5):889-900 [16680342.001]
  • [Cites] J Natl Cancer Inst. 2006 Aug 16;98(16):1158-61 [16912268.001]
  • [Cites] J Epidemiol. 2006 Sep;16(5):185-92 [16951537.001]
  • [Cites] Anticancer Agents Med Chem. 2006 Sep;6(5):389-406 [17017850.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2007 Feb;19(2):171-6 [17273005.001]
  • [Cites] Ann Epidemiol. 2007 Oct;17(10):821-6 [17606381.001]
  • [Cites] Asia Pac J Clin Nutr. 2008;17 Suppl 1:245-8 [18296347.001]
  • [Cites] Arh Hig Rada Toksikol. 2008 Mar;59(1):11-8 [18407867.001]
  • [Cites] Cancer Causes Control. 2008 Aug;19(6):577-84 [18231869.001]
  • [Cites] Int J Cancer. 2009 Feb 1;124(3):670-7 [18973231.001]
  • [Cites] Am J Epidemiol. 2008 Dec 15;168(12):1425-32 [18974083.001]
  • [Cites] BMJ. 2009;338:b929 [19325180.001]
  • [Cites] Int J Cancer. 2009 Aug 1;125(3):491-524 [19415743.001]
  • [Cites] Cancer Causes Control. 2009 Oct;20(8):1303-8 [19430969.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):289-94 [10861489.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):658-64 [11058886.001]
  • [Cites] J Food Prot. 2001 Aug;64(8):1268-70 [11510675.001]
  • [Cites] Nutr Cancer. 2000;38(2):186-91 [11525596.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):346-7 [11875696.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:159-72 [11890101.001]
  • [Cites] J Laryngol Otol. 2002 Jul;116(7):523-31 [12238672.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2003 Mar;24(3):192-5 [12816709.001]
  • [Cites] Oral Oncol. 2003 Oct;39(7):695-700 [12907209.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):207-13 [14693246.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Mar 1;19(5):497-510 [14987318.001]
  • [Cites] Asian Pac J Cancer Prev. 2004 Jan-Mar;5(1):58-65 [15075007.001]
  • [Cites] Nutr Cancer. 1984;6(4):220-8 [6545578.001]
  • [Cites] J Natl Cancer Inst. 1986 May;76(5):823-31 [3457969.001]
  • [Cites] Nutr Cancer. 1987;10(1-2):103-13 [3112746.001]
  • [Cites] Cancer Res. 1989 Feb 15;49(4):1049-51 [2912550.001]
  • [Cites] Nutr Cancer. 1992;17(1):27-31 [1574442.001]
  • [Cites] Cancer Causes Control. 1994 Sep;5(5):401-8 [7999961.001]
  • (PMID = 20395127.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010196-02; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coffee; 0 / Tea
  • [Other-IDs] NLM/ NIHMS192095; NLM/ PMC2891563
  •  go-up   go-down


80. Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, Turek LP, Hamsikova E: Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer; 2007 Feb 15;120(4):825-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibodies against E6 or E7 were associated with risk of cancer in the oral cavity (OR = 5.1, 1.2-22.4) and oropharynx (OR = 72.8, 16.0-330), and with disease characteristics: stage, grade and nodal status.
  • [MeSH-minor] Adenocarcinoma / etiology. Alcohol Drinking. Carcinoma, Mucoepidermoid / etiology. Case-Control Studies. DNA, Viral / analysis. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131312.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE1311-S1; United States / NIDCR NIH HHS / DE / DE13110; United States / FIC NIH HHS / TW / TW01500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / E2 protein, Human papillomavirus type 16; 0 / E6 protein, Human papillomavirus type 18; 0 / Oncogene Proteins, Viral
  •  go-up   go-down


81. Reid-Nicholson M, Kavuri S, Ustun C, Crawford J, Nayak-Kapoor A, Ramalingam P: Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation. Cancer; 2008 Oct 25;114(5):333-41
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin lymphoma that was once believed to occur primarily in the oral cavity of human immunodeficiency virus-positive individuals.
  • Two patients had the acquired immunodeficiency syndrome and 3 had second non-PBL related malignancies including endometrial carcinoma, lung adenocarcinoma, and small lymphocytic lymphoma.
  • However, although these findings may suggest PBL, a definitive diagnosis requires adjunctive studies including immunohistochemistry and flow cytometry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18683216.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Parekh DJ, Lin WC, Herrell SD: Optical spectroscopy characteristics can differentiate benign and malignant renal tissues: a potentially useful modality. J Urol; 2005 Nov;174(5):1754-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Promising results of optical signals have been reported in the literature for the diagnosis of Barrett's esophagus, oral cavity lesions, brain tumor margins, cervical intraepithelial neoplasia, skin cancer and bladder cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Precancerous Conditions / pathology. Spectrometry, Fluorescence
  • [MeSH-minor] Case-Control Studies. Diagnosis, Differential. Female. Humans. Kidney / pathology. Male. Reference Values. Sampling Studies. Sensitivity and Specificity. Tissue Culture Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2005 Nov;174(5):1723-4 [16217270.001]
  • (PMID = 16217277.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Sidransky D: The oral cavity as a molecular mirror of lung carcinogenesis. Cancer Prev Res (Phila); 2008 Jun;1(1):12-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The oral cavity as a molecular mirror of lung carcinogenesis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Prev Res (Phila). 2008 Jun;1(1):39-44 [19138934.001]
  • (PMID = 19138931.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5U01 CA084986; United States / NIDCR NIH HHS / DE / P50 DE019032; United States / NIDCR NIH HHS / DE / R37 DE012588; United States / NIDCR NIH HHS / DE / R01 DE012588; United States / NCI NIH HHS / CA / U01 CA084986
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS695561; NLM/ PMC4604561
  •  go-up   go-down






Advertisement